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Summary of findings {#CD010678-sec1-0001}
===================

Summary of findings for the main comparisonSummary of findings table 1**Artemether compared with quinine for treating children with severe malariaPatient or population:** Children with severe malaria **Settings:** Malaria‐endemic countries **Intervention:** Intramuscular artemether **Comparison:** Intravenous or intramuscular quinine**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskQuinineArtemetherDeath170 per 1000164 per 1000** (129 to 204)**RR 0.96** (0.76 to 1.2)1447 (12 trials)⊕⊕⊕⊝ **moderate**^1,2,3,4^**Coma resolution time**The mean coma resolution time ranged across control groups from **17.4 to 42.4 hours**The mean coma resolution time in the intervention groups was **5.45 hours shorter** (7.90 to 3.00 shorter)‐358 (6 trials)⊕⊕⊝⊝ **low**^3,5,6,7^**Neurological sequelae at discharge220 per 1000185 per 1000** (145 to 235)**RR 0.84** (0.66 to 1.07)968 (7 trials)⊕⊕⊝⊝ **low** ^1,2,3,8^**Parasite clearance time**The mean parasite clearance time ranged across control groups from **22.4 to 61.25 hours**The mean parasite clearance time in the intervention groups was **9.03 hours shorter** (11.43 to 6.63 shorter)‐420 (7 trials)⊕⊕⊕⊝ **moderate**^1,3,7,9^**Fever clearance time**The mean fever clearance time ranged across control groups from **18 to 61.25 hours**The mean fever clearance time in the intervention groups was **3.73 shorter** (6.55 to 0.92 shorter)‐457 (8 trials)⊕⊕⊝⊝ **low**^3,10,11,12^\*The **assumed risk** is the median control group risk across studies. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^2]

Summary of findings 2Summary of findings table 2**Artemether compared with quinine for treating adults with severe malariaPatient or population:** Adults with severe malaria **Settings:** Malaria endemic countries **Intervention:** Intramuscular artemether **Comparison:** Intravenous or intramuscular quinine**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskQuinineArtemetherDeath208 per 1000123 per 1000** (87 to 173)**RR 0.59** (0.42 to 0.83)716 (4 trials)⊕⊕⊕⊝ **moderate**^1,2,3,4^**Coma resolution time**‐‐Not pooled. Little difference.657 (2 trials)⊕⊕⊝⊝ **low**^1,5,6,\ 7^**Neurological sequelae at discharge4 per 100012 per 1000**\
(1 to 111)**RR 2.92** (0.31 to 27.86)560 (1 trial)⊕⊕⊝⊝ **low**^7,8^**Parasite clearance time**‐‐Not pooled. Little difference apparent.716 (4 trials)⊕⊕⊕⊝ **moderate**^1,3,6,9^**Fever clearance time**‐‐Not pooled. Little difference apparent.716 (4 trials)⊕⊕⊝⊝ **low**^1,3,6,10^\*The **assumed risk** is the median control group risk across studies. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^3]

Summary of findings 3Summary of findings table 3**Artemether compared with artesunate for treating adults with severe malariaPatient or population:** Adults with severe malaria **Settings:** Malaria endemic countries **Intervention:** Intramuscular artemether **Comparison:** Intravenous or intramuscular artesunate**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskArtesunateArtemetherDeath87 per 1000156 per 1000** (95 to 258)**RR 1.80** (1.09 to 2.97)494 (2 trials)⊕⊕⊕⊝ **moderate**^1,2,3,4^**Coma resolution time**‐‐Not pooled. No significant difference494 (2 trials)⊕⊕⊕⊝ **moderate**^1,3,5,6^**Neurological sequelae at discharge**‐‐‐0 (0 trials)‐**Parasite clearance time**‐‐Not pooled. No significant difference494 (2 trials)⊕⊕⊕⊝ **moderate**^1,3,6,7^**Fever clearance time**‐‐Not pooled. No significant difference494 (2 trials)⊕⊕⊝⊝ **low**^1,3,6,8^\*The **assumed risk** is the median control group risk across studies. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^4]

Background {#CD010678-sec1-0002}
==========

Description of the condition {#CD010678-sec2-0001}
----------------------------

Malaria is a febrile illness caused by *Plasmodium* parasites, which are transmitted to humans through the bite of infected female anopheline mosquitoes. Five species of *Plasmodium* cause this disease in humans, of which *P. falciparum* is the most common worldwide, and is responsible for almost all of the severe disease and deaths ([@CD010678-bbs2-0055]; [@CD010678-bbs2-0056]).

Severe malaria is diagnosed on the basis of a positive blood slide or antigen test for malaria, plus the presence of clinical or laboratory features of vital organ dysfunction. These include impaired consciousness, coma, convulsions, respiratory distress, shock (systolic blood pressure \< 70 mmHg in adults, \< 50 mmHg in children), jaundice, haemoglobinuria, hypoglycaemia, severe metabolic acidosis or anaemia ([@CD010678-bbs2-0057]). Cerebral malaria is one form of severe malaria, where the patient has some impairment of consciousness and cognition. This can vary from slight disorientation through to deep coma where the patient is unconscious and unrousable. Even with correct treatment cerebral malaria can cause a mortality rate of up to 20%, and a small proportion of people that survive infection can have persistent neurological sequelae ([@CD010678-bbs2-0043]).

People living in malaria‐endemic regions can develop a naturally acquired immunity to malaria through repeated exposure to the parasite over five to 10 years ([@CD010678-bbs2-0039]). This partial immunity is protective against the most severe forms of the disease, and as a consequence, in high transmission settings mortality from severe malaria is highest in young children and decreases with increasing age ([@CD010678-bbs2-0057]).

The World Health Organization (WHO) currently recommends parenteral artesunate as the first‐line treatment for severe malaria, followed by a complete course of an effective artemisinin‐based combination therapy (ACT) as soon as the patient can take oral medications ([@CD010678-bbs2-0057]). The WHO based their recommendation on evidence from two large multi‐centre clinical trials that demonstrated the superiority of intravenous artesunate over the standard treatment quinine ([@CD010678-bbs2-0037]; [@CD010678-bbs2-0038]). A Cochrane Review of available data concluded that treating people that have severe malaria with artesunate instead of quinine would reduce the risk of death by 39% in adults and 24% in children ([@CD010678-bbs2-0053]).

Description of the intervention {#CD010678-sec2-0002}
-------------------------------

Artesunate is only one of a number of antimalarials derived from artemisinin, which is extracted from the herb *Artemesia annua* and is the active ingredient in a Chinese herbal remedy for fever. Once ingested or injected, artemisinin derivatives undergo conversion to dihydroartemisinin, the active metabolite, which has a broad spectrum of activity against the blood stage asexual *Plasmodium* parasites ([@CD010678-bbs2-0050]; [@CD010678-bbs2-0054]). Artemisinin derivatives clear parasites from the peripheral blood quicker than other antimalarials, but only artesunate has been shown to impact mortality.

Unlike artesunate, artemether is poorly soluble in water and the parenteral formulation is only available as a pre‐mixed oil‐based solution for intramuscular injection (80 mg/mL for use in adults and 40 mg/mL for children). The standard dose is 3.2 mg/kg on admission followed by 1.6 mg/kg once daily until oral therapy is tolerated ([@CD010678-bbs2-0057]). Peak plasma concentrations typically occur around six hours after intramuscular injection, but in severely ill children with poor peripheral perfusion, absorption can be highly erratic ([@CD010678-bbs2-0044]; [@CD010678-bbs2-0048]; [@CD010678-bbs2-0049]).

Conversely, artesunate is supplied as a dry powder for mixing with sodium bicarbonate prior to either intravenous or intramuscular injection ([@CD010678-bbs2-0057]). Compared with artemether, the absorption of artesunate is more reliable with peak plasma concentrations following intramuscular injection occurring at around one hour ([@CD010678-bbs2-0041]; [@CD010678-bbs2-0042]; [@CD010678-bbs2-0051]). These more favourable pharmacokinetic properties of artesunate moved research attention away from artemether and artesunate now has a stronger evidence‐base and is the preferred therapy ([@CD010678-bbs2-0053]; [@CD010678-bbs2-0057]).

Why it is important to do this review {#CD010678-sec2-0003}
-------------------------------------

A number of African countries incorporated intramuscular artemether into their national guidelines prior to the WHO recommendation for artesunate. Systematic reviews concluded that intramuscular artemisinin derivatives (including both artesunate and artemether) were not inferior to quinine in preventing deaths from malaria, but were safer and easier to administer ([@CD010678-bbs2-0036]; [@CD010678-bbs2-0045]; [@CD010678-bbs2-0047]).

Following the WHO recommendation for artesunate as the preferred treatment for severe malaria, there is a need to re‐evaluate the role of intramuscular artemether in the management of severe malaria in adults and children.

Objectives {#CD010678-sec1-0003}
==========

To assess the efficacy and safety of intramuscular artemether versus any other parenteral medication in the treatment of severe malaria in adults and children.

Methods {#CD010678-sec1-0004}
=======

Criteria for considering studies for this review {#CD010678-sec2-0004}
------------------------------------------------

### Types of studies {#CD010678-sec3-0001}

Randomized controlled trials (RCTs).

### Types of participants {#CD010678-sec3-0002}

Adults and children (under 15 years of age) with severe malaria.

### Types of interventions {#CD010678-sec3-0003}

#### Intervention {#CD010678-sec4-0001}

Intramuscular artemether

#### Control {#CD010678-sec4-0002}

Any other parenteral medication for the treatment of severe malaria

### Types of outcome measures {#CD010678-sec3-0004}

#### Primary outcomes {#CD010678-sec4-0003}

Death from any cause

#### Secondary outcomes {#CD010678-sec4-0004}

Coma resolution timeNeurological sequelae (such as blindness, deafness, hemiplegia and others)Time to hospital dischargeParasite clearance timeFever clearance timeNeed for blood transfusionSevere anaemiaAdverse events (including hypoglycaemia, tinnitus, nausea, vomiting, haematological and cardiac‐related adverse events)

Search methods for identification of studies {#CD010678-sec2-0005}
--------------------------------------------

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press and in progress).

### Electronic searches {#CD010678-sec3-0005}

#### Databases {#CD010678-sec4-0005}

We searched the following databases on 09 April 2014 using the search terms detailed in [Table 6](#CD010678-tbl-0006){ref-type="table"}:  Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 4), published in *The Cochrane Library*; MEDLINE (1966 to April 2014); EMBASE (1974 to April 2014), LILACS (1982 to April 2014) and ISI Web of Science (1900 to April 2014). We also searched the WHO clinical trial registry platform, ClinicalTrials.gov and the metaRegister of Controlled Trials (mRCT) up to 09 April 2014 for ongoing trials using \'artemether\', \'severe malaria\', \'complicated malaria\', \'artesunate\', \'arteether\', and \'child\*\' as search terms.Table 1Search strategy**Search setCIDG SR^1^CENTRALMEDLINE^2^Embase^2^LILACS^2^ISI Web of Science**1malariaMalaria ti, ab, MeSHMalaria ti, ab, MeSHMalaria ti, ab, Emtreemalariamalaria2artemetherArtemether ti, abArtemether ti, abArtemether ti, ab, Emtreeartemetherartemether3Artemisinin\*Artemisinin\* ti, abArtemisinin\* ti, abArtemisinin\* ti, abArtemisinin\*Artemisinin\*4intramuscularIntramuscular ti, abIntramuscular ti, abIntramuscular ti, abintramuscularintramuscular5parenteralInjections, Intramuscular \[MeSH\]Injections, Intramuscular \[MeSH\]Intramuscular drug administration \[Emtree\]parenteralparenteral62 or 3Parenteral ti, abParenteral ti, abParenteral drug administration \[Emtree\]2 or 32 or 374 or 52 or 32 or 32 or 34 or 54 or 581 and 5 and 74 or 5 or 64 or 5 or 64 or 5 or 61 and 5 and 71 and 5 and 79‐1 and 7 and 81 and 7 and 81 and 7 and 8‐Randomised clinical trial\*10‐‐‐‐‐8 and 9[^5]

### Searching other resources {#CD010678-sec3-0006}

#### Conference proceedings {#CD010678-sec4-0006}

We searched relevant proceedings of the following meetings for trial information; Multilateral Initiative on Malaria (MIM) Pan‐African Malaria Conference, European Congress of Tropical Medicine and American Society of Tropical Medicine and Hygiene (09 April 2014).

#### Researchers {#CD010678-sec4-0007}

We contacted researchers working in the field and the WHO for unpublished and ongoing trials.

#### Reference lists {#CD010678-sec4-0008}

We checked the reference lists of existing reviews and of all trials identified by the above methods.

Data collection and analysis {#CD010678-sec2-0006}
----------------------------

### Selection of studies {#CD010678-sec3-0007}

Two authors (EE and EEE) independently screened the literature search results and obtained the full reports of such potentially relevant trials. EE and EEE independently applied the inclusion criteria to the full reports using an eligibility form and scrutinized publications to ensure each trial was included only once. We resolved any disagreements through discussion with a third author and, when necessary, by consulting a member of the Cochrane Infectious Diseases Group (CIDG) editorial team. Also, we listed the excluded studies and the reasons for their exclusion.

### Data extraction and management {#CD010678-sec3-0008}

EE and EEE independently extracted data using a specifically developed piloted data extraction form. We resolved any disagreements through discussion with all of the review authors and, when necessary, by consulting a member of the CIDG editorial team. We contacted the corresponding publication author in the case of unclear information or missing data. For each outcome we aimed to extract the number of participants randomized and the number analysed in each treatment group. For dichotomous outcomes, we recorded the number of participants experiencing the event and the number assessed in each treatment group. For continuous outcomes, we extracted arithmetic means and standard deviations for each treatment group, together with the numbers assessed in each group.

Where baseline proportions of participants in the intervention and control arms in whom antipyretics were administered varied, we only included trials that reported fever clearance time and provided additional information about antipyretics use at baseline for participants in both intervention and control arm to avoid confounding in the summary estimate for fever clearance. Where there was significant difference between antipyretic use at baseline in intervention and control arms, we only reported fever clearance time in a table. We defined cure rates in this review as time from first dose to first negative parasite reading for two consecutive readings.

### Assessment of risk of bias in included studies {#CD010678-sec3-0009}

EE and EEE independently assessed the risk of bias of each trial using a risk of bias form. We attempted to contact the trial authors if this information was not specified or if it was unclear. We resolved any disagreements by discussion between review authors. Six components were assessed: generation of the randomization sequence, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other biases (such as the trial stopped early). We categorized our judgements as either \'low\', \'high\', or \'unclear\' risk of bias, and described our reasons for doing so.

### Measures of treatment effect {#CD010678-sec3-0010}

We calculated results using risk ratios for dichotomous data, and mean difference values for continuous data, and presented these effect estimates with 95% confidence intervals (CI). We treated time‐to‐event outcomes as continuous data and accordingly mean difference calculated from mean time in intervention versus control groups.

### Unit of analysis issues {#CD010678-sec3-0011}

For multiple arm trials, we combined all relevant experimental intervention groups of the trial into a single group, and also combined all relevant control intervention groups into a single control group. For dichotomous outcomes, both the sample sizes and the numbers of people with events were added across groups. For continuous outcomes, we combined means and standard deviations using methods described in the *Cochrane Handbook for Systematic Reviews of Interventions*.

### Dealing with missing data {#CD010678-sec3-0012}

We analysed data according to the intention‐to treat principle (all randomized participants should be analysed in the groups to which they were originally assigned). If there were discrepancies between the number randomized and the number analysed, we calculated the percentage loss to follow‐up for each treatment group and reported this information.

However, if for some trials it was unclear whether there was loss to follow‐up, we entered the number analysed into [@CD010678-bbs2-0052] whenever these figures were available. By attempting to carry out a complete case analysis, we avoided making assumptions about the outcomes of participants lost to follow‐up. Where possible, we contacted authors for missing data.

### Assessment of heterogeneity {#CD010678-sec3-0013}

We looked for statistical heterogeneity by inspecting the forest plots for overlapping CIs, applying the Chi^2^ test (P \< 0.10 considered statistically significant) and the I^2^ statistic (I^2^ value \< 50% used to denote moderate levels of heterogeneity).

### Assessment of reporting biases {#CD010678-sec3-0014}

We planned to construct funnel plots to look for evidence of publication bias provided we included a sufficient number of trials to make this informative.

### Data synthesis {#CD010678-sec3-0015}

We analysed the data using [@CD010678-bbs2-0052]. In the first instance, we applied a fixed‐effect meta‐analysis. However, if we detected moderate heterogeneity but still considered it appropriate to combine the trials, we then used a random‐effects approach. Where heterogeneity was very high such that meta‐analysis was not appropriate, we displayed the results in forest plots or tables but did not combine the results. Where data were only presented as medians and ranges, we presented the results in tables.

We presented the main results of the review alongside a GRADE appraisal of the quality of evidence in the \'Summary of Findings\' tables.

### Subgroup analysis and investigation of heterogeneity {#CD010678-sec3-0016}

We grouped the analysis and results by children and adults. We reported results by whether the studies were carried out in Africa or in Asia. We examined whether loading dose or quinine influenced outcomes.

### Sensitivity analysis {#CD010678-sec3-0017}

We conducted a sensitivity analysis to investigate the robustness of the results to the risk of bias components by including only trials that concealed the allocation and had low incomplete outcome data (\< 10%).

#### Assessment of the quality of evidence {#CD010678-sec4-0009}

We assessed the quality of the evidence following the GRADE approach and defined \'quality\' as an assessment of our confidence in the estimates of effect ([@CD010678-bbs2-0040]).

Results {#CD010678-sec1-0005}
=======

Description of studies {#CD010678-sec2-0007}
----------------------

See the [Characteristics of included studies](#CD010678-sec2-0015){ref-type="sec"} section for details of the included trials.

### Results of the search {#CD010678-sec3-0018}

We conducted the literature search up to 09 April 2014 and identified 77 references (see [Figure 1](#CD010678-fig-0001){ref-type="fig"}).Figure 1Study flow diagram.

### Included studies {#CD010678-sec3-0019}

We included 18 RCTs, enrolling 2662 participants, in this review. Twelve trials enrolled children only (1447 participants aged between six months and 15 years), and six trials enrolled older children and adults (1215 participants aged between 13 and 79 years).

#### Location {#CD010678-sec4-0010}

The trials in children were primarily conducted in Africa: Nigeria (five trials), Sudan (two trials), the Gambia (one trial), Kenya (one trial), Malawi (one trial), and Mali (one trial); with only one trial from Asia (India).

Five adult trials were conducted in Asia: Vietnam (three trials), and Thailand (two trials); and one in Oceania; Papua New Guinea (one trial). We have attached a three letter country code to each trial ID to aid forest plot interpretation.

#### Interventions {#CD010678-sec4-0011}

All 12 trials in children compared artemether with quinine. Artemether was given by intramuscular injection, with a loading dose of 3.2 mg/kg body weight followed by maintenance doses of 1.6 mg/kg for three to six days (see [Table 7](#CD010678-tbl-0007){ref-type="table"} for details). Only three trials followed this with oral therapy once tolerated ([@CD010678-bbs2-0008]; [@CD010678-bbs2-0015]; [@CD010678-bbs2-0016]). For quinine, nine trials administered the WHO recommended loading dose of 20 mg/kg of intravenous or intramuscular quinine followed by a maintenance dose of 10 mg/kg. However, [@CD010678-bbs2-0016] administered the maintenance dose at 12‐hourly intervals instead of eight‐hour intervals (see [Table 7](#CD010678-tbl-0007){ref-type="table"}).Table 2Characteristics of trials comparing artemether and quinine in children**Trial IDYear of studyAge limitsQuinine dosing scheduleArtemether dosing scheduleLoading doseMaintainanceFollow‐on therapyLoading doseMaintainanceFollow‐on therapy**[@CD010678-bbs2-0001]2002\'Children\'20 mg/kg IV10 mg/kg IV every eight hours for 72 hoursOral quinine for 7 days3.2 mg/kg IM1.6 mg/kg IM once daily for 4 daysNone[@CD010678-bbs2-0002]20076 months to 12 yrs20 mg/kg IV or IM10 mg/kg IV/IM every eight hoursNone3.2 mg/kg IM1.6 mg/kg IM once daily for 2 daysNone[@CD010678-bbs2-0004]2001\< 14 yrs20 mg/kg IV10 mg/kg IV every eight hoursQuinine to complete 7 days1.6 mg/kg IM twice daily1.6 mg/kg IM once daily for 5 daysNone[@CD010678-bbs2-0007]20043 months to 15 yrs20 mg/kg IV10 mg/kg IV every eight hoursQuinine 10 mg/kg every eight hours3.2mg/kg IM twice daily1.6 mg/kg IM once daily for 4 daysNone[@CD010678-bbs2-0008]19965 months to 12 yrs20 mg/kg IV10 mg/kg IV every eight hoursSP once3.2 mg/kg IM1.6 mg/kg IM once daily for 4 daysSP once[@CD010678-bbs2-0009]1998Mean age about 4 yrs10 mg/kg IV10 mg/kg IV every eight hoursQuinine to complete 7 days3.2 mg/kg IM1.6 mg/kg IM 12 hrs later, then once daily for 2 daysNone[@CD010678-bbs2-0010]199911 months to 5 yrs20mg/kg IV10mg/kg IV every eight hoursQuinine to complete 7 days3.2 mg/kg IM1.6 mg/kg IM once daily for 4 daysNone[@CD010678-bbs2-0011]20091 to 12yrs10 mg/kg IV10 mg/kg IV every eight hoursQuinine to complete 7 days1.6 mg/kg IM twice daily1.6 mg/kg IM once daily for 4 daysNone[@CD010678-bbs2-0013]19963 months to 15yrs10 mg/kg IV10 mg/kg IV every eight hoursQuinine to complete 7 days1.6 mg/kg IM twice daily1.6 mg/kg IM once daily for 4 daysNone[@CD010678-bbs2-0015]1994Mean age of 3 yrs20 mg/kg IV10 mg/kg IV every eight hours for at least 2 dosesSP once3.2 mg/kg IM1.6 mg/kg IM once daily for 2 days at leastSP once[@CD010678-bbs2-0016]19941 to 9yrs20 mg/kg IV10 mg/kg IV every twelve hoursQuinine to complete 5 days3.2 mg/kg IM1.6 mg/kg IM once daily for 3 daysSP once^1^[@CD010678-bbs2-0018]19931 to 5yrs20 mg/kg IV10 mg/kg IV every eight hoursQuinine to complete 7 days3.2 mg/kg IM1.6 mg/kg IM once daily for 4 daysNone[^6]

In adults, four trials compared artemether with quinine ([@CD010678-bbs2-0003]; [@CD010678-bbs2-0005]; [@CD010678-bbs2-0006]; [@CD010678-bbs2-0014]) and two trials compared artemether with artesunate ([@CD010678-bbs2-0012]; [@CD010678-bbs2-0017]). Artemether was given intramuscularly, over three to seven days with slight variations in dosing (see [Table 8](#CD010678-tbl-0008){ref-type="table"} and [Table 9](#CD010678-tbl-0009){ref-type="table"}) and all four trials administered quinine at the WHO‐recommended loading dose.Table 3Characteristics of trials comparing artemether and quinine in adults**Trial IDYear of studyAge limitsQuinine dosing scheduleArtemether dosing scheduleLoading doseMaintainanceFollow‐on therapyLoading doseMaintainanceFollow‐on therapy**[@CD010678-bbs2-0003]199615 to 79 yrs20 mg/kg IM10 mg/kg IM every eight hoursQuinine or mefloquine to complete 7 days4 mg/kg IM2 mg/kg IM once daily for 4 daysQuinine or mefloquine to complete 7 days[@CD010678-bbs2-0005]199115 to 45 yrs20 mg/kg IV10 mg/kg every eight hours for 7 daysQuinine to complete 7 days160 mg IM80 mg IM once daily for 6 daysNone[@CD010678-bbs2-0006]199415 to 55 yrs20 mg/kg IV10 mg/kg every eight hours for 7 daysQuinine to complete 7 days160 mg IM80 mg IM once daily for 6 daysNone[@CD010678-bbs2-0014]1995\> 12 yrs20 mg/kg IV10 mg/kg IV every eight hoursQuinine to complete 7 days3.2 mg/kg IM1.6 mg/kg IM once daily for 4 daysNone[^7]Table 4Characteristics of studies comparing artemether and artesunate in adults**Trial IDYear of studyAge limitsArtemether dosing scheduleArtesunate dosing scheduleLoading doseMaintainanceFollow‐on therapyLoading doseMaintainanceFollow‐on therapy**[@CD010678-bbs2-0012]200315 to 77 yrs3.2 mg/kg IM1.6 mg/kg IM dailyNone2.4 mg/kg IM1.2 mg/kg IM once daily2 mg/kg of artesunate to complete 7 days[@CD010678-bbs2-0017]199415 to 66 yrs200 mg IM100 mg IM once daily for 3 daysMefloquine once120 mg IM or IV60 mg IM or IV once daily for 3 daysMefloquine once[^8]

#### Supportive care {#CD010678-sec4-0012}

All 12 trials in children reported measurement of blood glucose on admission, but only nine trials reported any subsequent active monitoring for hypoglycaemia.

Only one trial in adults reported measuring blood glucose on admission and monitored hypoglycaemia up to 24 hours after admission ([@CD010678-bbs2-0003]).

#### Outcome measures {#CD010678-sec4-0013}

All 18 trials reported death, a measure of coma resolution, fever clearance and parasite clearance as outcomes. Eleven trials reported neurological sequelae at discharge. Only two trials ([@CD010678-bbs2-0002]; [@CD010678-bbs2-0012]) reported duration of hospital stay and two trials ([@CD010678-bbs2-0003]; [@CD010678-bbs2-0010]) reported on the number of children requiring blood transfusions. Eleven trials ([@CD010678-bbs2-0001]; [@CD010678-bbs2-0003]; [@CD010678-bbs2-0004]; [@CD010678-bbs2-0005]; [@CD010678-bbs2-0006]; [@CD010678-bbs2-0007]; [@CD010678-bbs2-0008]; [@CD010678-bbs2-0012]; [@CD010678-bbs2-0014]; [@CD010678-bbs2-0016]; [@CD010678-bbs2-0018]) reported on adverse events including episodes of hypoglycaemia. We have listed the outcome definitions used in the included trials in [Table 10](#CD010678-tbl-0010){ref-type="table"}.Table 5Definitions of outcome measures used in the review**Trial IDComa resolution timeFever clearance timeParasite clearance timeHypoglycaemia**[@CD010678-bbs2-0001]Mean value (h) reported and defined as a Blantyre coma score of 5 recorded for at least 24 hoursMean value (h) reported and defined as the time after which the temperature remained normal (axillary temperature \< 37.5°C)Mean value (h) reported and defined as the time passed from admission and start of treatment until two consecutive negative smears. Blood films repeated every 8 hours.Number of episodes (n/N) reported but not defined[@CD010678-bbs2-0002]Proportions with coma resolution on D3 reported but not definedProportions with fever clearance on D3 and D14 reported and defined as body temperature ≤ 37.5°C after commencement of treatmentProportions with parasite clearance on D3 and D14. Parasite clearance was taken as adequate clinical and parasitological response (ACPR) at days 3 and 14. Parasite count taken on D0, D3 and D14.Not reported[@CD010678-bbs2-0003]Median value (h) reported and defined as the time to reach a score of 15 on the Glasgow Coma ScaleMedian value (h) reported but not defined.Median value (h) reported and defined as the time to Assessed every 4 hours for the first 24 hours and every 6 hours until three consecutive negative blood smearsNumber of episodes (n/N) reported but not defined[@CD010678-bbs2-0004]Glasgow coma scale was used in grading the level of consciousness of the patients\
every eight hoursMean value (h) reported and defined as time to clearance of feverMean value (h) reported but not definedNot reported[@CD010678-bbs2-0005]Unclear if values reported are means or medians (h)Mean value (h) reported and defined as time for the temperature to fall below 37.5°C and remain that value for 72 hoursMean value (h) reported and defined as the time for the parasite count to fall below the level of microscopic detection (thick film)Not reported[@CD010678-bbs2-0006]Median value (h) reported and defined as the time taken for the patients to recover completely from unconciousnessMean value (h) reported and defined as time for the temperature to fall below 37.5°C and remain that value for 72 hoursMedian value (h) reported and defined as the time taken for parasite count to fall below the level of microscopic detection (thick film)Not reported[@CD010678-bbs2-0007]Mean value (h) reported and defined as the time to normalization of consciousnessMean value (h) reported but not definedMean value (h) reported and defined as time till negative parasitaemia resultNot reported[@CD010678-bbs2-0008]Median value (h) reported but not describedMedian value (h) reported but not describedMedian value (h) reported but not described. Every four hours until clearanceNot reported[@CD010678-bbs2-0009]Mean value (h) reported and defined as the interval between onset of therapy and the attainment of full consciousnessMean value (h) reported and defined as the interval between the onset of therapy and the time the body temperature is ≤ 37°C and remained soDefined as two successive thick blood films done at 12 hours interval are negative for asexual forms of plasmodium speciesNot reported[@CD010678-bbs2-0010]Mean value (h) reported and defined as time to regain full consciousnessMean value (h) reported and defined as the time for temperature to fall below 37.5°C and remain so for at least 48 hoursMean value (h) reported and defined as\
the time from start of drug administration to the first of two consecutive negative thick smears remaining negative until day 7Not reported[@CD010678-bbs2-0011]Mean value (h) reported and defined as time to attainment of a Blantyre score of 5 for at least 24 hours from initiation of treatmentMean value (h) reported but not definedMean value (h) reported but not defined. Thick and thin film done on D0 and repeated on Days 3, 7 and 14Not reported[@CD010678-bbs2-0012]Median value (h) reported and defined as time to Glasgow coma score of 15.Median value (h) reported and defined as the time for temperature to fall below 37.5°C and remain soMedian value (h) reported and defined as the time to clear all parasitesNumber of episodes (n/N) reported but not defined[@CD010678-bbs2-0013]Mean value (h) reported and defined as time to regaining consciousnessMean value (h) reported and defined as the time for temperature to fall below 37.5°CMean value (h) reported and defined as time to clear parasites measured every six hours till clearanceNot reported[@CD010678-bbs2-0014]Median value (h) reported but not definedMedian value (h) reported and defined as a temperature \<37.5 °C on two successive readingsMedian value (h) reported and defined as as the time at which the blood films were negative for *P. falciparum* for at least eight hoursNumber of episodes (n/N) reported but not defined[@CD010678-bbs2-0015]Median value (h) reported and defined as time required for a\
child to achieve a Blantyre Coma Score of 5Median value (h) reported and defined as the time at which the rectal or axillary temperature dropped below 37.5°C and remained \< 37.5°C for 24 consecutive hoursMedian value (h) reported and defined as the time at which the first of two negative (0 parasites/200 WBC) thick blood films was prepared. Every four hours till clearanceNot reported[@CD010678-bbs2-0016]Median value (h) reported and defined as time to regain full consciousnessMedian value (h) reported and defined as time needed for the rectal temperature to fall below 38.0°C for at least 24 hoursMedian value (h) reported and defined as time needed for all parasites to clear relative to parasite density at admission and assessed every 12 hours till clearanceNumber of episodes (n/N) reported and defined as a blood glucose level below 40 mg/dL (2.2 mmol/L)[@CD010678-bbs2-0017]Median value (h) reported and defined as time to regain full consciousnessMedian value (h) reported and defined as time for axillary temperature to fall to, and remain for ≥ 24 hours at 37.5°C or lowerMedian value (h) reported and defined as time to clear parasitesNot reported[@CD010678-bbs2-0018]Mean value (h) reported but not definedMean value (h) reportedMean value (h) reported and defined as the time for parasitaemia to be cleared and to remain so up to Day 7. Assessed every six hours during period of coma and then every 12 hours.Not reported[^9]

Other outcomes reported by trials which we did not include in this review were time to death ([@CD010678-bbs2-0008]; [@CD010678-bbs2-0015]; [@CD010678-bbs2-0016]), survival rate ([@CD010678-bbs2-0005]; [@CD010678-bbs2-0006]), cause of death ([@CD010678-bbs2-0005]), fatality rate ([@CD010678-bbs2-0017]), time to ambulation ([@CD010678-bbs2-0010]; [@CD010678-bbs2-0012]), time to sit unaided and time to drink ([@CD010678-bbs2-0012]; [@CD010678-bbs2-0018]), time to eating ([@CD010678-bbs2-0012]), gametocyte carriage ([@CD010678-bbs2-0001]), recrudescence ([@CD010678-bbs2-0001]; [@CD010678-bbs2-0007]; [@CD010678-bbs2-0015]; [@CD010678-bbs2-0018]), 28th day cure rate ([@CD010678-bbs2-0013]; [@CD010678-bbs2-0016]; [@CD010678-bbs2-0018]). Other outcomes included duration of parenteral treatment and time for plasma lactate levels to fall below 2.5 mmol/L ([@CD010678-bbs2-0003]).

### Excluded studies {#CD010678-sec3-0020}

We excluded 14 trials and listed the reasons for their exclusion in the \'[Characteristics of excluded studies](#CD010678-sec2-0016){ref-type="sec"}\' section.

Risk of bias in included studies {#CD010678-sec2-0008}
--------------------------------

See [Figure 2](#CD010678-fig-0002){ref-type="fig"} for a summary of the risk of bias assessments. We presented further details in the \'[Characteristics of included studies](#CD010678-sec2-0015){ref-type="sec"}\' tables.Figure 2Risk of bias summary: review authors\' judgements about each risk of bias item for each included trial.

### Allocation {#CD010678-sec3-0021}

Seven trials were at low risk of bias regarding the generation of allocation sequence while one trial was at high risk of bias ([@CD010678-bbs2-0002]). Ten trials were at unclear risk of bias because review authors did not provide enough information to permit us to make a judgement.

Eleven trials were at low risk of bias regarding allocation concealment and the remaining trials provided insufficient information to make a judgement.

### Blinding {#CD010678-sec3-0022}

In all trials, except [@CD010678-bbs2-0003] and [@CD010678-bbs2-0012], investigators and participants were aware of treatment allocation. Participants were also not blind to the intervention as two different routes (intramuscular (artemether) and intravenous (quinine) were used to administer the interventions. Blinding was unlikely to affect the assessment of outcome death in all trials. In one trial, microscopists were blinded to the intervention and clinical status of the patients ([@CD010678-bbs2-0004]). The other subjective outcomes were thus at high risk of bias in all open included trials or at unclear risk of bias where trial provided did not provide information.

### Incomplete outcome data {#CD010678-sec3-0023}

Fourteen trials reported no losses to follow‐up. The remaining four trials ([@CD010678-bbs2-0002]; [@CD010678-bbs2-0013]; [@CD010678-bbs2-0014]; [@CD010678-bbs2-0015]) reported over 10 per cent attrition in either one or both trial arms. Two trials used the per protocol number of participants as a denominator in the analysis ([@CD010678-bbs2-0015]; [@CD010678-bbs2-0014]). The other two trials used the number of participants randomized as the denominator in the analysis.

### Selective reporting {#CD010678-sec3-0024}

We did not detect any evidence of selective outcome reporting.

### Other potential sources of bias {#CD010678-sec3-0025}

We did not identify any other sources of bias.

Effects of interventions {#CD010678-sec2-0009}
------------------------

See: [Table 1](#CD010678-tbl-0001){ref-type="table"}; [Table 2](#CD010678-tbl-0002){ref-type="table"}; [Table 3](#CD010678-tbl-0003){ref-type="table"}

### Artemether versus quinine {#CD010678-sec3-0026}

### Children {#CD010678-sec3-0027}

Twelve trials were conducted in children, Eleven in Africa and one in Asia. All used loading doses of quinine.

**Death:** there was no overall difference in all‐cause mortality between intramuscular artemether and intravenous quinine (RR 0.96, 95% CI 0.76 to 1.20; 12 trials, 1447 participants, [Analysis 1.1](#CD010678-fig-00101){ref-type="fig"}). However, these 12 trials were too small to detect or exclude clinically important differences, and the overall meta‐analysis remains significantly underpowered to prove equivalence (see [Table 11](#CD010678-tbl-0011){ref-type="table"} and [Table 12](#CD010678-tbl-0012){ref-type="table"}). The current total sample size has adequate power to exclude effects as large as seven extra deaths per 100 patients.Table 6Optimal information size calculations; dichotomous outcomes**OutcomeType of testProportion in control group^3^Proportion in Intervention groupEstimated RRTotal sample size^1,2^Death**Superiority0.170.1360.803514Equivalence0.170.14 to 0.20^4^‐6592**Neurological sequelae**Superiority0.250.200.802184Equivalence0.250.22 to 0.28^4^‐8760[^10]Table 7Optimal information size calculations; continuous outcomes**OutcomeType of testMean in control group^3^Mean in Intervention group^4^SD of outcomeTotal sample size^1,2^Coma resolution time**Superiority251920350Equivalence2519 to 3120382**Parasite clearance time**Superiority423620350Equivalence4236 to 4820382**Fever clearance time**Superiority484220350Equivalence4836 to 5420382[^11]

**Coma resolution time:** the mean coma resolution time was about five hours shorter with artemether (26 hours) compared with quinine (30.55 hours) (MD ‐5.45 hours, 95% CI ‐7.90 to ‐3.00; six trials, 358 participants, [Analysis 1.3](#CD010678-fig-00103){ref-type="fig"}). This effect was largest in trials without adequate allocation concealment and therefore at unclear or high risk of bias. A sensitivity analysis excluding these trials found no significant difference between groups. In addition, three trials reported median time to coma resolution (see [Table 13](#CD010678-tbl-0013){ref-type="table"}). Two trials found no significant difference ([@CD010678-bbs2-0008]; [@CD010678-bbs2-0015]), and one trial found the median time to be longer with artemether (26 hours versus 20 hours, P = 0.046, [@CD010678-bbs2-0016]). Two other trials ([@CD010678-bbs2-0007]; [@CD010678-bbs2-0011]) reported mean coma resolution time as mean (SD) but the data was not normally distributed and so we have reported this an additional table ([Table 13](#CD010678-tbl-0013){ref-type="table"}).Table 8Additional data: Artemether versus quinine in children**Pre‐specified outcomeTrial reported outcomeTrialNo. of participantsArtemetherQuinineComparative results reported in articleComa resolution time (h)**Median\
(IQR)[@CD010678-bbs2-0008]16012 (2.8 to 96)13 (2.8 to 96)Not significantly differentMedian\
(IQR)[@CD010678-bbs2-0016]57626 (15 to 48)20 (12 to 43)P = 0.046Median\
(IQR)[@CD010678-bbs2-0015]16418 (8 to 30)20 (10 to 54)Not significantly differentComa recovery (%) on Day 3[@CD010678-bbs2-0002]9015.9%21.4%RR = 0.763 (95% CI 0.065 to 9.015)Mean (SD)[@CD010678-bbs2-0011]324.5 (13.05)9 (24.59)P = 0.523Mean (SD)[@CD010678-bbs2-0007]6730.57 (29.02)25.15 (31.62)P = 0.53**Time to hospital discharge**% spending less than one week in\
hospital[@CD010678-bbs2-0002]9061.76%71.74%P = 0.829**Fever clearance (h)**Median\
(IQR)[@CD010678-bbs2-0008]16032 (4 to 86)32 (4 to 96)Not significantly different[@CD010678-bbs2-0016]57630 (16 to 48)33 (12‐60)P = 0.8[@CD010678-bbs2-0015]16431 (24 to 52)45 (33 to 60)\"Significant\"Fever clearance (%) on Day 3[@CD010678-bbs2-0002]9090.0%87.7%P = 0.753**Parasite clearance (h)**Median\
(IQR)[@CD010678-bbs2-0008]16039.5 (24 to 45)48\
(37 to 56)P \< 0.001[@CD010678-bbs2-0016]57648 (36 to 60)60 (48 to 72)P \< 0.001[@CD010678-bbs2-0015]16432 (25 to 36)40 (32 to 48)\'significant\'Parasite clearance (%) on Day 3[@CD010678-bbs2-0002]9099.0%\
n = 4496.8%\
n = 46P = 0.422**Needing blood transfusion**‐[@CD010678-bbs2-0016]‐‐‐\"The two groups were similar in terms of the need for blood transfusions,and the incidence of secondary bacterial infections (data not shown).\"[^12]

**Neurological sequelae:** there was no overall difference in the risk of neurological sequelae at hospital discharge between artemether (185 per 1000) and quinine (220 per 1000) (RR 0.84, 95% CI 0.66 to 1.07; seven trials, 968 participants, [Analysis 1.4](#CD010678-fig-00104){ref-type="fig"}). Again these trials were too small to enable us to confidently detect or exclude what may be clinically important differences between treatments (see [Table 11](#CD010678-tbl-0011){ref-type="table"}). The overall meta‐analysis is adequately powered to exclude effects larger than eight additional sequelae per 100 patients.

Three trials continued to monitor patients with neurological sequelae after hospital discharge. [@CD010678-bbs2-0013] found no difference at day seven, [@CD010678-bbs2-0015] found most sequelae had resolved and [@CD010678-bbs2-0016] found no difference at day 28 ([Analysis 1.5](#CD010678-fig-00105){ref-type="fig"}).

**Parasite clearance time (PCT):** the mean parasite clearance time in children was approximately nine hours shorter with artemether (MD ‐9.03 hours, 95% CI ‐11.43 to ‐6.63; seven trials, 420 participants, [Analysis 1.6](#CD010678-fig-00106){ref-type="fig"}. The statistical significance of this result remained after we excluded trials at unclear or high risk of selection bias. The mean parasite clearance times for artemether and quinine were 36.25 and 43.18 hours respectively.

Three additional trials reported median parasite clearance time and all showed a statistically significant benefit with artemether (see [Table 13](#CD010678-tbl-0013){ref-type="table"}). One trial ([@CD010678-bbs2-0009]) expressed parasite clearance as the proportion of patients with parasite clearance at 72 hours and at seven days, with no statistically significant differences between groups (see [Analysis 1.7](#CD010678-fig-00107){ref-type="fig"}). Trials differed with respect to the frequency with which they repeated malaria blood smears (see [Table 10](#CD010678-tbl-0010){ref-type="table"}).

**Fever clearance time (FCT):** eight trials reported mean fever clearance time with a statistically significant reduction of about three hours with artemether overall (MD ‐3.73 hours, 95% CI ‐6.55 to ‐0.92; eight trials, 457 participants, [Analysis 1.8](#CD010678-fig-00108){ref-type="fig"}). The mean fever clearance times for artemether and quinine were 43.69 and 46.26 hours respectively. However, only two of the individual trials showed a statistically significant difference between the groups. Three trials in children reported median fever clearance time and two trials found no statistically significant difference between the two groups (see [Table 13](#CD010678-tbl-0013){ref-type="table"}).

The definitions of fever varied across the included trials. Six trials used a cut off of body temperature less than 37.5°C from initiation of treatment to define fever clearance (see [Table 10](#CD010678-tbl-0010){ref-type="table"}).

**Need for blood transfusion:** one trial reported on the number of patients requiring blood transfusions for severe malarial anaemia in both artemether and quinine arms ([@CD010678-bbs2-0010]) (see [Analysis 1.9](#CD010678-fig-00109){ref-type="fig"}). No statistically significant difference was observed between both arms (RR 1.27, 95% CI 0.62 to 2.59; 103 participants, one trial).

**Adverse effects:** six trials reported on the frequency of adverse events ([@CD010678-bbs2-0001]; [@CD010678-bbs2-0004]; [@CD010678-bbs2-0007]; [@CD010678-bbs2-0008]; [@CD010678-bbs2-0016]; [@CD010678-bbs2-0018]). Two trials reported no adverse events had occurred during the trial duration (see [Table 14](#CD010678-tbl-0014){ref-type="table"}). One trial reported the absence of adverse events in the artemether arm ([@CD010678-bbs2-0007]). No trial reported discontinuation of medication.Table 9Adverse event monitoring and reporting**Study IDSample sizeClinical symptoms monitoringBiochemistryHaematologicalElectrocardiogramAdditional comments on adverse events**[@CD010678-bbs2-0001]41Not reportedNot reportedNot reportedNot reported\"Neurological deficits were not observed in any patient during the follow‐up period\"[@CD010678-bbs2-0002]90Not reportedNot reportedNot reportedNot reportedNone[@CD010678-bbs2-0003]560Clinical assessment every 4 hours for the first 24 hours and 6 hourly afterwardsBlood glucose, lactate and cytokine levels measured 4, 8, 12 and 24 hours after admissionFull blood count on admissionPre‐treatment and 12 hours after initiation of treatment on Day 0, 4 hours after last dose and at dischargeNone[@CD010678-bbs2-0004]46Lumbar puncture\
Chest x‐ray on day 0Blood Glucose, Renal Function Test,\
Liver Function Test and Serum Electrolyte on Days 0 and 3Full Blood Count on Days 0 and 3Day 0\"No serious side effects of either of the drugs were observed in our study\...\... Closer and more frequent monitoring and larger sample size would have probably revealed more subtle adverse drug effects.\"[@CD010678-bbs2-0005]26Clinical evaluation daily for at least 7 days\
Lumbar puncture\
Chest x‐ray on day 0Biochemistry on Days 0, 2, 4 and 7Full Blood Count on Days 0, 2, 4 and 7On admission for all patients; then once daily and every six hours for quinine and artemether patients respectively\"The side effects in the quinine group were dizziness and vertigo. No side effects were detected with artemether\".[@CD010678-bbs2-0006]102Clinical evaluation on admission and twice daily for at least 7 days\
Lumbar puncture\
Chest x‐ray on day 0Biochemistry on Days 0, 2, 4 and 7FBC on Days 0, 2, 4 and 7On admission for all patients; then once daily and every six hours for quinine and artemether patients respectivelyQTc prolongation and tinnitus were the major adverse events in Quinine arm.\
Mild transient pain at injection site for approximately 15 mins after artemether treatment.[@CD010678-bbs2-0007]67Clinical examination daily on Days 1 to7, and 14Blood glucose on Days 1, 2, 3, 5, 7 and 14\
Urea and Serum Electrolyte, transaminases, phosphatases on Days 1, 3, 5, 7 and 14FBC on Days 1, 3, 5, 7 and 14Once daily on Days 1, 3, 5, 7 and 14None[@CD010678-bbs2-0008]160Clinical assessment on admission, then at six, then 12 hour intervals till dischargeBlood glucose, urea, electrolytes, blood gases and when clinically indicatedFBC on Day 0 and when clinically indicated\
Blood cultures on Day 0On admission and at 6, 24, 30, 48 and 54 hoursNone[@CD010678-bbs2-0009]37Clinical assessment on Day 0Urea and electrolyte\
Blood sugar and liver function test on Day 0FBC on Day 0NoneNone[@CD010678-bbs2-0010]103Clinical assessments on Days 0, 3, 7, 14, 28Blood glucose, Urea and creatinine, electrolytes on Days 0, 3, 7, 14, 28WBC count on Days 0, 3, 7, 14, 28None\"No adverse reactions to the two drugs were recorded during the study\".[@CD010678-bbs2-0011]32Clinical examination on Days 0 to 7 and 14NoneNoneNoneNone[@CD010678-bbs2-0012]370Clinical examination on admission\
Chest x‐ray on admission\
Lumbar punctureBlood urea nitrogen, serum creatinine, aspartate aminotransferase, alanine transaminase, plasma lactateFull blood count on admissionNoneNone[@CD010678-bbs2-0013]77Clinical evaluation on admission and every six hours on Days 0 to 4, and then once daily on Days 14, 21 and 28Blood glucose, serum creatinine, serum aspartate, aminotransferase on Day 0WBC, Haemoglobin on Days 0 and 3NoneNone[@CD010678-bbs2-0014]33Chest X‐ray on admissionRenal and Liver function tests on admission, Days 3 and 7Full Blood Count on Days 0, 3 and 7NoneNone[@CD010678-bbs2-0015]183CSF collected on admissionBlood glucose,\
Blood pH, on D0 (every four hours for the first 24 hoursHaematocrit every eight hours\
Full Blood Count, urea and electrolytes on Days 0, 3, 7 and 28On admission, 6, 48,54 and 96 hours\"Of the initial 127 patients on whom serial electrocardiographic tracings were made, more patients in the quinine group showed prolongation of the corrected QT intervals after treatment, but the differences were not statistically or clinically significant.\" \"There were no significant differences between the two treatment groups in terms of adverse effects associated with antimalarial treatment (i.e. new signs and symptoms which develop within seven days of the start of treatment).\"[@CD010678-bbs2-0016]576Clinical examination on Day 0\
Lumbar puncture on admissionBlood glucose on admission, after 4hours and 12 hoursPCV, Haemoglobin, Blood culture on Day 0NoneNone[@CD010678-bbs2-0017]124Clinical examination on admissionBlood glucose, serum creatinine, serum bilirubin on admissionFull blood count on admissionNoneNone[@CD010678-bbs2-0018]54Clinical examination twice daily\
Spinal tapsUrea and Electrolyte, on days 3, 7, 14, 28PCV on days 3, 7, 14, 28On admission, at 4 and 6 hoursNone

Only two trials reported episodes of hypoglycaemia ([Analysis 1.10](#CD010678-fig-00110){ref-type="fig"}). Other adverse effects reported were QT prolongation, local skin reaction at the injection site, abscess, urticarial rash, pruritus, supraventricular tachycardia and urinary tract infection.. However, these trials were insufficiently powered to detect differences in adverse events. The trials had similar definitions of adverse events (included only adverse effects that could not be attributable to malaria).

**Time to hospital discharge:** none of the included trials reported time to discharge. One trial reported the proportion of patients that spent less than one week in hospital and found no significant difference between groups (see [Table 13](#CD010678-tbl-0013){ref-type="table"}).

### Adults {#CD010678-sec3-0028}

Four trials were conducted in adults, three in Asia and one in Oceania. All used loading doses of quinine.

**Death:** artemether resulted in fewer deaths compared with quinine (RR 0.59, 95% CI 0.42 to 0.83; four trials, 716 participants, [Analysis 1.1](#CD010678-fig-00101){ref-type="fig"}) from trials conducted mostly in Asia.

**Coma resolution time:** three trials reported a measure of coma resolution time. [@CD010678-bbs2-0003] reported median coma resolution time, which was shorter in the quinine arm. [@CD010678-bbs2-0006] found both arms to be comparable in terms of coma resolution time. The third trial, [@CD010678-bbs2-0005] reported mean coma resolution time but the data were incompletely reported (see [Table 15](#CD010678-tbl-0015){ref-type="table"}).Table 10Additional data: Artemether versus quinine in adults**Pre‐specified outcomeTrial reported outcomeTrialNo. of participantsArtemetherQuinineComparative results reported in articleComa resolution time (h)**Median (IQR)[@CD010678-bbs2-0003]56066 (30 to 132)48 (20 to 84)P = 0.003Median (Range)[@CD010678-bbs2-0006]9748 (6 to 144)48 (6 to 144)Not significantly different**Fever clearance (h)**Median (IQR)[@CD010678-bbs2-0003]560127 (60 to 216)90 (54 to 144)\< 0.001Median (Range)[@CD010678-bbs2-0014]3332 (20 to 112)48 (28 to 88)P = 0.034Median (Range)[@CD010678-bbs2-0006]9779 (16 to 147)84 (36 to 144)Not significantly different**Parasite clearance (h)**Median (IQR)[@CD010678-bbs2-0003]56072 (54 to 102)90 (66 to 108)\< 0.001Median (range)[@CD010678-bbs2-0014]3348(4 to 72)52 (12 to112)P = 0.381Median (Range)[@CD010678-bbs2-0006]9754 (30 to 164)78 (18 to 168)P = 0.007[^13]

**Neurological sequelae:** only one trial [@CD010678-bbs2-0003] reported neurological sequelae at discharge. Four neurological sequelae were reported with no difference between groups (one trial; 560 participants, [Analysis 1.4](#CD010678-fig-00104){ref-type="fig"}).

**Parasite clearance time (PCT):** one trial reported mean parasite clearance time but showed no statistically significant difference between artemether and quinine (MD 1.70 hours, 95% CI ‐15.56 to 18.96; 26 participants, one trial, [Analysis 1.6](#CD010678-fig-00106){ref-type="fig"}). Three other trials reported median parasite clearance time. Two trials reported a significantly shorter time to clearance of parasites with artemether ([@CD010678-bbs2-0003]; [@CD010678-bbs2-0006]; see [Table 13](#CD010678-tbl-0013){ref-type="table"}). [@CD010678-bbs2-0014] found no significant difference between artemether and quinine with respect to parasite clearance time.

Trials differed with respect to the frequency with which they repeated malaria blood smears (see [Table 10](#CD010678-tbl-0010){ref-type="table"}).

**Fever clearance time (FCT):** four trials reported a measure of fever clearance time. [@CD010678-bbs2-0005] reported mean fever clearance time and found a statistically significant reduction of about 30 hours with artemether (MD ‐29.7 hours, 95% CI ‐54.14 to ‐5.26; 26 participants, one trial). The other three trials in adults reported median fever clearance time and two ([@CD010678-bbs2-0003]; [@CD010678-bbs2-0014]) reported a statistically significant reduction in fever clearance time in favour of quinine and artemether respectively. [@CD010678-bbs2-0006] found both groups were comparable (see [Table 15](#CD010678-tbl-0015){ref-type="table"}).

The definitions of fever varied across the included trials. Three trials used a cut off of body temperature less than 37.5°C from initiation of treatment to define fever clearance (see [Table 10](#CD010678-tbl-0010){ref-type="table"}).

**Need for blood transfusion:** one trial reported on the number of patients requiring blood transfusions for severe malarial anaemia in both artemether and quinine arms ([@CD010678-bbs2-0003]) (see [Analysis 1.9](#CD010678-fig-00109){ref-type="fig"}). No statistically significant difference was observed between both arms (RR 0.97, 95% CI 0.73 to 1.29; 560 participants, one trial).

**Adverse events:** one trial reported episodes of hypoglycaemia ([Analysis 1.10](#CD010678-fig-00110){ref-type="fig"}). Other adverse effects reported were abscess, induration at injection site, leg discomfort, chest infection and gastrointestinal bleeding. However, these trials were insufficiently powered to detect differences in adverse events. The trials had similar definitions of adverse events (included only adverse effects that could not be attributable to malaria).

### Artemether versus artesunate {#CD010678-sec3-0029}

### Adults {#CD010678-sec3-0030}

Two trials were conducted in adults; both from Asia.

**Death:** only two trials directly compared intramuscular artemether and intravenous artesunate. Overall, the risk of all‐cause mortality was significantly higher following treatment with artemether (RR 1.80, 95% CI 1.09 to 2.97; 494 participants, two trials, [Analysis 2.1](#CD010678-fig-00201){ref-type="fig"}). However, both trials were too small to detect or exclude clinically important differences, and the overall meta‐analysis remains significantly underpowered to prove superiority (see [Table 11](#CD010678-tbl-0011){ref-type="table"} and [Table 12](#CD010678-tbl-0012){ref-type="table"}).

**Coma resolution time:** two trials reported median coma resolution times. Both trials reported a shorter coma resolution time with artesunate. However, these differences were not statistically significant ([Table 16](#CD010678-tbl-0016){ref-type="table"}).Table 11Additional data: Artemether versus artesunate in adults**Pre‐specified outcomeTrial reported outcomeTrialNo. of participantsArtemetherArtesunate IMArtesunate IVComparative results reported in articleComa resolution time (h)**Median (range)[@CD010678-bbs2-0012]37072(2 to 2232) n = 18460(4 to 2136) n = 186‐P = 0.11Median (95% CI)[@CD010678-bbs2-0017]12447 (31 to 63)30 (18 to 42)24 (4 to 44)‐**Fever clearance (h)**Median (range)[@CD010678-bbs2-0012]370108 (0 to 888) n = 184108 (0 to 888) n = 186‐P = 0.27Median (95% CI)[@CD010678-bbs2-0017]12448 (38 to 58)36 (30 to 42)30 (18 to 42)‐**Parasite clearance (h)**Median (range)[@CD010678-bbs2-0012]37072\
(2 to 204)72\
(7 to 330)‐P = 0.97Median (95% CI)[@CD010678-bbs2-0017]12430 (26 to 34)24 (15 to 33)24 (15 to 33)Not statistically significant[^14]

**Parasite clearance time:** two trials found no overall difference in median parasite clearance time ([@CD010678-bbs2-0012]; [@CD010678-bbs2-0017]).

**Fever clearance time:**[@CD010678-bbs2-0012] found no statistically significant difference in median fever clearance time between intramuscular artemether and intravenous artesunate. The additional small trial ([@CD010678-bbs2-0017]) found a benefit in favour of artesunate although this was not statistically significant.

**Need for blood transfusion:**[@CD010678-bbs2-0012] found no difference between treatments with respect to the need for blood transfusion in adult severe malaria patients (RR 1.01, 95% CI 0.78 to 1.32; 370 participants, one trial, [Analysis 2.2](#CD010678-fig-00202){ref-type="fig"}).

**Adverse effects:** only [@CD010678-bbs2-0012] reported adverse events. The risk of hypoglycaemia was significantly higher in adults treated with intramuscular artemether compared with artesunate (RR 1.70. 95% CI 0.4 to 7.24; 370 participants, one trial, [Analysis 2.4](#CD010678-fig-00204){ref-type="fig"}).

Discussion {#CD010678-sec1-0006}
==========

Summary of main results {#CD010678-sec2-0010}
-----------------------

We included 18 RCTs, enrolling 2662 children and adults with severe malaria. Eleven trials were conducted in Africa and seven trials were undertaken in Asia.

### Artemether versus quinine {#CD010678-sec3-0031}

For children (trials mostly conducted in Africa), there is probably little or no difference in the risk of death between intramuscular artemether and quinine (*moderate quality evidence*). Artemether may shorten the coma recovery time by about five hours (*low quality evidence*), and may reduce the number of children with subsequent neurological sequelae (*low quality evidence).* Artemether probably shortens the parasite clearance time by about nine hours (*moderate quality evidence*), and may shorten the fever clearance time by about three hours (*low quality evidence*).

For older children (\> 15 years) and adults in Asia, artemether probably reduces deaths compared with quinine (*moderate quality evidence*), but larger trials are required to have full confidence in this finding.

### Artemether versus artesunate {#CD010678-sec3-0032}

Artemether and artesunate have only been compared in two trials in adults from Asia, and mortality is probably higher with intramuscular artemether (*moderate quality evidence*) but larger trials are required to have confidence in this finding.

Overall completeness and applicability of evidence {#CD010678-sec2-0011}
--------------------------------------------------

Although 16 trials directly compared artemether versus quinine, none were adequately powered to detect clinically important differences. The total number of participants included in these trials (2163 participants) remains far short of the 7429 participants included in trials of artesunate versus quinine. The majority of data comparing artemether and quinine were from trials conducted in sub‐Saharan Africa where artemether is most widely used.

The two trials directly comparing artemether and artesunate were conducted in adults in Asia, and the results are therefore poorly applicable to children in Africa. However, in the absence of direct comparisons in children, the low quality evidence of equivalence between artemether and quinine suggests that artesunate will be as superior to artemether as it has been shown to be superior to quinine.

Artemether is prone to erratic and partial absorption and takes longer to achieve peak plasma concentrations as demonstrated in animal and human studies. These pharmacokinetic attributes make artemether that is injected intramuscularly less readily available in the human body and may explain the difference in outcomes between artesunate and intramuscular artemether we have observed in this review.

Quality of the evidence {#CD010678-sec2-0012}
-----------------------

We assessed the quality of the evidence using the GRADE approach and have presented it in three \'Summary of Findings\' tables ([Table 1](#CD010678-tbl-0001){ref-type="table"}; [Table 2](#CD010678-tbl-0002){ref-type="table"}; [Table 3](#CD010678-tbl-0003){ref-type="table"}).

The evidence of equivalence between intramuscular artemether and intravenous quinine in children is of moderate quality due to the small sample sizes of the included trials and the overall lack of power to fully exclude clinically important differences.

Similarly, we downgraded the evidence for reductions in mortality in adults treated with artemether compared with quinine, and artesunate compared with artemether, to moderate due to imprecision. Larger trials are needed to have full confidence in these effects.

Authors\' conclusions {#CD010678-sec1-0007}
=====================

Although there is a lack of direct evidence comparing artemether with artesunate, artemether is probably less effective than artesunate at preventing deaths from severe malaria. In circumstances where artesunate is not available, artemether is an alternative to quinine.Larger, adequately powered clinical trials are necessary for conclusive evidence on the relative effects of artemether. However, given the low bioavailability of artemether when given intramuscularly, it is unlikely that these trials will be done or indeed whether they are necessary.

The academic editor for this review was Dr Michael Eisenhut; Dr David Sinclair provided support in the preparing the \'Summary of findings\' tables.

The protocol for this review was developed during the Reviews for Africa Fellowship Programme organized by the Nigerian Branch of the South Africa Cochrane Centre in July 2012. The UK Department for International Development (DFID) supports this programme through the Effective Health Care Research Consortium (EHCRC) at the Liverpool School of Tropical Medicine (LSTM). This document is an output from a project funded by UKaid for the benefit of developing countries. The views expressed are not necessarily those of UKAid or the Department for International Development (DFID).

The editorial base for the Cochrane Infectious Diseases Group is funded by UKaid from the UK Government for the benefit of developing countries.

Comparison 1Artemether versus quinineOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Death](#CD010678-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Artemether versus quinine, Outcome 1 Death.16Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only1.1 Children121447Risk Ratio (M‐H, Fixed, 95% CI)0.96 \[0.76, 1.20\]1.2 Adults4716Risk Ratio (M‐H, Fixed, 95% CI)0.59 \[0.42, 0.83\][2 Death: Time since admission to hospital](#CD010678-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Artemether versus quinine, Outcome 2 Death: Time since admission to hospital.1Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only2.1 Death within 24 hours141Risk Ratio (M‐H, Fixed, 95% CI)0.35 \[0.02, 8.10\][3 Coma resolution time (hours)](#CD010678-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Artemether versus quinine, Outcome 3 Coma resolution time (hours).6Mean Difference (IV, Fixed, 95% CI)Subtotals only3.1 Children6358Mean Difference (IV, Fixed, 95% CI)‐5.45 \[‐7.90, ‐1.00\][4 Neurological sequelae at discharge](#CD010678-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Artemether versus quinine, Outcome 4 Neurological sequelae at discharge.8Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only4.1 Children7968Risk Ratio (M‐H, Fixed, 95% CI)0.84 \[0.66, 1.07\]4.2 Adults1560Risk Ratio (M‐H, Fixed, 95% CI)2.92 \[0.31, 27.86\][5 Neurological sequelae at follow‐up](#CD010678-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Artemether versus quinine, Outcome 5 Neurological sequelae at follow‐up.2566Risk Ratio (M‐H, Fixed, 95% CI)0.82 \[0.49, 1.38\]5.1 Day 71134Risk Ratio (M‐H, Fixed, 95% CI)0.76 \[0.27, 2.14\]5.2 Day 281432Risk Ratio (M‐H, Fixed, 95% CI)0.84 \[0.46, 1.53\][6 Parasite clearance time](#CD010678-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Artemether versus quinine, Outcome 6 Parasite clearance time.8446Mean Difference (IV, Fixed, 95% CI)‐8.82 \[‐11.20, ‐6.45\]6.1 Children7420Mean Difference (IV, Fixed, 95% CI)‐9.03 \[‐11.43, ‐6.63\]6.2 Adults126Mean Difference (IV, Fixed, 95% CI)1.70 \[‐15.56, 18.96\][7 Proportion with parasite clearance](#CD010678-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Artemether versus quinine, Outcome 7 Proportion with parasite clearance.174Risk Ratio (M‐H, Fixed, 95% CI)0.88 \[0.75, 1.04\]7.1 At 72 hours137Risk Ratio (M‐H, Fixed, 95% CI)0.88 \[0.70, 1.11\]7.2 At 7 days137Risk Ratio (M‐H, Fixed, 95% CI)0.88 \[0.70, 1.11\][8 Fever clearance time (hours)](#CD010678-fig-00108){ref-type="fig"}Analysis 1.8Comparison 1 Artemether versus quinine, Outcome 8 Fever clearance time (hours).9Mean Difference (IV, Fixed, 95% CI)Subtotals only8.1 Children8457Mean Difference (IV, Fixed, 95% CI)‐3.73 \[‐6.55, ‐0.92\]8.2 Adults126Mean Difference (IV, Fixed, 95% CI)‐29.70 \[‐54.14, ‐5.26\][9 Need for blood transfusion](#CD010678-fig-00109){ref-type="fig"}Analysis 1.9Comparison 1 Artemether versus quinine, Outcome 9 Need for blood transfusion.2Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only9.1 Children1103Risk Ratio (M‐H, Fixed, 95% CI)1.27 \[0.62, 2.59\]9.2 Adults1560Risk Ratio (M‐H, Fixed, 95% CI)0.97 \[0.73, 1.29\][10 Episodes of hypoglycaemia](#CD010678-fig-00110){ref-type="fig"}Analysis 1.10Comparison 1 Artemether versus quinine, Outcome 10 Episodes of hypoglycaemia.3Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only10.1 Children2617Risk Ratio (M‐H, Fixed, 95% CI)0.68 \[0.44, 1.05\]10.2 Adults1560Risk Ratio (M‐H, Fixed, 95% CI)0.44 \[0.30, 0.64\][11 Adverse events](#CD010678-fig-00111){ref-type="fig"}Analysis 1.11Comparison 1 Artemether versus quinine, Outcome 11 Adverse events.6Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only11.1 QT prolongation2229Risk Ratio (M‐H, Fixed, 95% CI)3.10 \[1.33, 7.19\]11.2 Local skin reactions1576Risk Ratio (M‐H, Fixed, 95% CI)0.12 \[0.03, 0.50\]11.3 Abscess21136Risk Ratio (M‐H, Fixed, 95% CI)0.20 \[0.04, 0.90\]11.4 Urticarial rash1576Risk Ratio (M‐H, Fixed, 95% CI)0.33 \[0.01, 8.15\]11.5 Supraventricular tachycardia154Risk Ratio (M‐H, Fixed, 95% CI)0.23 \[0.01, 4.59\]11.6 Pruritus167Risk Ratio (M‐H, Fixed, 95% CI)0.34 \[0.01, 8.13\]11.7 Urinary tract infection154Risk Ratio (M‐H, Fixed, 95% CI)3.46 \[0.15, 81.36\]11.8 Induration at injection site133Risk Ratio (M‐H, Fixed, 95% CI)15.44 \[0.94, 253.49\]11.9 Leg discomfort1560Risk Ratio (M‐H, Fixed, 95% CI)0.69 \[0.22, 2.16\]11.10 Chest infection1560Risk Ratio (M‐H, Fixed, 95% CI)1.11 \[0.81, 1.53\]11.11 GI bleeding1560Risk Ratio (M‐H, Fixed, 95% CI)0.79 \[0.52, 1.20\]

Comparison 2Artemether versus artesunateOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Death](#CD010678-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Artemether versus artesunate, Outcome 1 Death.2Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only1.1 Adults2494Risk Ratio (M‐H, Fixed, 95% CI)1.80 \[1.09, 2.97\][2 Need for blood transfusion](#CD010678-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Artemether versus artesunate, Outcome 2 Need for blood transfusion.1Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only2.1 Adults1370Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.78, 1.32\][3 Episodes of hypoglycaemia](#CD010678-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Artemether versus artesunate, Outcome 3 Episodes of hypoglycaemia.1Risk Ratio (M‐H, Fixed, 95% CI)Totals not selected[4 Adverse events](#CD010678-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Artemether versus artesunate, Outcome 4 Adverse events.1Risk Ratio (M‐H, Fixed, 95% CI)Totals not selected4.1 Spontaneous bleeding1Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]

In the protocol, we specified that we would include only trials in children (aged \< 15 years). However, we amended the inclusion criteria to include trials in adults and children.

We said we would explore data by drug regimen, type of severe malaria (cerebral versus non‐cerebral malaria), time since admission to hospital, length of follow‐up and geographical region, but data were insufficient.

Characteristics of included studies \[ordered by study ID\] {#CD010678-sec2-0015}
===========================================================

[@CD010678-bbs2-0001]MethodsTrial design: Open label RCT Trial dates: November 2001 to January 2002ParticipantsNumber of participants: 41 children enrolled Inclusion criteria: Children with severe malaria (age range not stated); cerebral malaria, repeated convulsions severe anaemia with haemoglobin \<5g/dL, hyper parasitaemia (parasite count \> 100,000 rings/µL or combinations of these criteria.\
Exclusion criteria: None statedInterventions1.  Intramuscular artemether (Kunming Pharmaceuticals; China)\
Loading dose of 3.2 mg/kg on day 1Followed by 1.6 mg/kg once daily for the following four days   \
2. Intravenous quinine \
Loading dose of 20 mg/kg of quinine dihydrochloride in 10 mL/kg 5% dextrose over four hoursFollowed by 10 mg/kg of quinine dihydrochloride in 10 mL/kg 5% dextrose solution over four hours, every eight hours for at least 72 hoursFollowed by oral quinine (for seven days as soon as patient could tolerate)OutcomesOutcomes included in the review:\
DeathComa resolution timeParasite clearance timeFever clearance timeEpisodes of hypoglycaemia\
Outcomes not included in the review:\
Gametocyte carriageRecrudescenceNotesLocation: Outpatient clinic in New Halfa, Eastern Sudan Transmission: \"meso‐endemic\"\
Funding: None stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Each child was randomized\". No further details provided.Allocation concealment (selection bias)Low risk\"Envelopes containing the assigned treatment were opened sequentially at the time when each patient was recruited to the study\".Blinding (performance bias and detection bias) Objective outcome: DeathLow riskDescribed as open‐label. However, lack of blinding is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskAn open‐label trial.Incomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐up were reported.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0002]MethodsTrial design: RCT\
Trial dates: July to October 2007ParticipantsNumber of participants: 90 children enrolled\
Inclusion criteria: Children between six months and 12 years of age presenting with fever (\> 37.5°C ) and *P. falciparum* infection with one or more general danger signs of severe or complicated malaria based on the WHO criteria for severe malaria\
Exclusion criteria: Serious concomitant illness, for example, sickle cell anaemia, HIV, tuberculosis and other chronic diseases, severe malnutrition, known hypersensitivity to one of the trial drugs.Interventions1. Intramuscular artemether (Paluther; May and Baker)\
Loading dose of 3.2 mg/kg on admissionFollowed by 1.6 mg/kg once daily for two days\
2.Intravenous or intramuscular quinine (Quinimax; Sanofi)\
Loading dose 20 mg salt/kg body weight on admissionFollowed by 10 mg/kg every eight hours; the infusion rate did not exceed 5 mg salt/kg per hourOutcomesOutcomes included in the review:\
DeathProportion of patients recovered from coma on day 3Proportion of patients discharged by day 7Proportion of patients with fever clearance on day 3 and day 14Proportion of patients with parasite clearance on day 3 and day 14\
Outcomes not included in the review:\
Hospital bed‐daysNotesLocation: Federal Medical Centre, Birnin Kudu, Jigawa State of Nigeria\
Transmission: Stable perennial transmission\
Funding: None stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High risk\"Patients were assigned to receive quinine if the last digit of their hospital identification number was odd and to receive artemether if the last digit of their hospital identification number was even or zero\".Allocation concealment (selection bias)High riskTrial authors did not describe any methods of allocation concealment, and this would not be possible using this randomization method.Blinding (performance bias and detection bias) Objective outcome: DeathLow riskNo blinding was described. However, lack of blinding is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskNo blinding is described, and blinding would not be feasible.Incomplete outcome data (attrition bias) All outcomesHigh riskLosses to follow‐up at day 14 were \> 10% in both trial arms.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0003]MethodsTrial design: Double blind RCT\
Trial dates: Not statedParticipantsNumber of participants: 560 adults aged 15 to 79 years enrolled\
Inclusion criteria: Patients were included in the trial if they (or an accompanying relative) gave informed consent, had asexual forms of *P. falciparum* on a peripheral‐blood smear, were older than 14 years, were not in the first trimester of pregnancy, were not intravenous drug users, had received less than 3 g of quinine or two doses of artemisinin or a derivative in the previous 48 hours, and had one or more of the following: a score on the Glasgow Coma Scale of less than 11 (indicating cerebral malaria); anaemia (hematocrit, 20 percent), with a parasite count exceeding 100,000 parasites/mm^3^ on a peripheral‐blood smear; jaundice (serum bilirubin, 2.5 mg/dL (50 mmol per litre)), with a parasite count of more than 100,000 parasites/mm^3^ on a peripheral‐blood smear; renal impairment (urine output, 400 mL per 24 hours; and serum creatinine, 3 mg/dL (250 mmol/L)); hypoglycaemia (blood glucose, 40 mg/dL (2.2 mmol/L)); hyperparasitaemia (10% parasitaemia); and systolic blood pressure below 80 mmHg with cool extremities (indicating shock).\
Exclusion criteria: None statedInterventions1.Intramuscular artemether (Kunming Pharmaceutical)\
Loading dose of 4 mg/kgFollowed by 2 mg/kg eight hourly for a minimum of three daysFollowed by either a single oral dose of 15 mg of mefloquine or oral dose of 10 mg quinine sulphate for up to four days\
2.Intramuscular quinine\
Loading dose of 20 mg/kgFollowed by 10 mg/kg per kilogram eight hourlyFollowed by either a single oral dose of 15 mg/kg of mefloquine or oral dose of 10 mg/kg quinine sulphate for up to four daysOutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelaeFever clearance timeParasite clearance timeHypoglycaemiaNeed for blood transfusionAdverse effects\
Outcomes not included in the review:\
Duration of parenteral antimalarial treatmentTime for plasma lactate level to fall below 2.5 mmol/LNotesLocation: Special Research Ward, Centre for Tropical Diseases, Ho Chi Minh City, Vietnam\
Transmission: Not stated\
Funding: Wellcome Trust***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskTrial authors provided no information on methods of sequence generation.Allocation concealment (selection bias)Low risk\"The drugs for each patient were placed in a coded sealed envelope and the envelopes were randomized in blocks of 20. Once a patient was enrolled in the study the envelope was opened\".Blinding (performance bias and detection bias) Objective outcome: DeathLow risk\"To maintain blinding, a separate team of nurses, who were not otherwise involved with the care of the study patients, drew up and gave the injections. The drugs were kept in an opaque packet in a locked cabinet during the study\". Both interventions were administered by intramuscular injection so blinding was feasible.\"Blinding (performance bias and detection bias) Subjective outcomes: OthersLow risk\"To maintain blinding, a separate team of nurses, who were not otherwise involved with the care of the study patients, drew up and gave the injections. The drugs were kept in an opaque packet in a locked cabinet during the study\". Both interventions were administered by intramuscular injection so blinding was feasible.\"Incomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐up were recorded.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0004]MethodsTrial design: Open RCT\
Trial dates: April 2000 to July 2001ParticipantsNumber: 46 children aged 6 months to 12 years enrolled\
Inclusion criteria: Asexual forms of *P. falciparum* from peripheral blood smear. One or more clinical manifestations of severe malaria present which included -- cerebral malaria, severe anaemia (haemoglobin \< 5 g/dL or hematocrit \< 15%) metabolic abnormalities (hypoglycaemia: plasma glucose \< 40 mg/dL or \< 2.2 mmol/L), algid malaria (associated with peripheral circulatory failure or shock), black‐water fever, renal failure, spontaneous bleeding (thrombocytopenia, DIC), pulmonary edema and jaundice.\
Exclusion criteria: History of having received artemether /quinine within 24 hours preceding admission. Severe protein energy malnutrition or clinical/laboratory evidence of other significant illness not attributable to severe malaria.Interventions1. Intramuscular artemether\
Loading dose of 1.6 mg/kg twice a day on admissionFollowed by 1.6 mg/kg once a day for five days\
2. Intravenous quinine\
Loading dose of 20 mg/kgFollowed by 10 mg/kg every eight hours by infusionFollowed by oral quinine sulphate once the patient was conscious, for a total period of seven days\
Supportive therapy was given to all patients.OutcomesOutcomes included in the review:\
DeathParasite clearance timeFever resolution timeComa recovery\
Outcomes not included in the review: NoneNotesLocation: Inpatient unit of Department of Pediatrics, and Parasitology laboratory, Department of Microbiology, Uttar Pradesh, India\
Transmission: Unknown\
Funding: None stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskTrial authors provided no information on methods of sequence generation.Allocation concealment (selection bias)Unclear riskTrial authors provided no information on allocation concealment.Blinding (performance bias and detection bias) Objective outcome: DeathLow riskAn open‐label trial is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias) Subjective outcomes: OthersLow risk\"The slides for malarial parasites were transported to the parasitology laboratory where the person examining the slides was unaware of the clinical status of the patient and also the treatment assignment group\".Incomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐up were recorded.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0005]MethodsTrial design: RCT\
Trial dates: May to December 1991ParticipantsNumber of participants: 26 adults aged 15 to 45 years enrolled\
Inclusion criteria: Patients with severe falciparum malaria (WHO definition) with no history of antimalarials within 24 hours prior to admission, aged between 15 to 45 years and weighed 45 to 60kg\
Exclusion criteria: None statedInterventions1. Intramuscular artemether (Arthermin®)\
Loading dose of 160 mgFollowed by 80 mg once daily for six days\
2. Intravenous quinine\
Loading dose of 20 mg/kgFollowed by 10 mg/kg eight hourly for seven daysFollowed by quinine sulphate tablets as soon as oral medication was possibleOutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelaeFever clearance timeParasite clearance timeAdverse effects\
Outcomes not included in the review:\
Survival rateCause of deathNotesLocation: Prapokklao Hospital, Chantaburi, Thailand\
Transmission: Not stated\
Funding: Support from United Medical Ltd., Bangkok (provided artemether)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"The patients were randomized to receive either quinine or artemether\".Allocation concealment (selection bias)Unclear riskTrial authors provided no information on allocation concealment.Blinding (performance bias and detection bias) Objective outcome: DeathLow riskTrial authors provided no information on blinding.\
However, lack of blinding is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskTrial authors provided no information on blinding, however it may not be feasible due to different routes of administration for both interventions.Incomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐up reported.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0006]MethodsTrial design: RCT\
Trial dates:1992 to 1994ParticipantsNumber of participants: 102 adults aged between 15 and 55 years enrolled\
Inclusion criteria: Male and female (non‐pregnant) patients with severe falciparum malaria (WHO definition) with no history of antimalarial treatment within 24 hours before admission aged 15 to 65 years and weighing 45 to 75kg\
Exclusion criteria: Patients with concurrent diseases were excludedInterventions1. Intramuscular artemether\
Loading dose of 160 mgFollowed by 80 mg once daily for six days\
2. Intravenous quinine\
Loading dose of 20 mg/kgFollowed by 10 mg/kg eight hourly for seven daysFollowed by quinine sulphate tablets as soon as oral medication was possibleOutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelaeFever clearance timeParasite clearance timeAdverse effects\
Outcomes not included in the review:\
Survival rateNotesLocation: Prapokklao Hospital, Chantaburi, Thailand\
Transmission: Not stated\
Funding: UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskCentral randomization at WHO Office.Allocation concealment (selection bias)Low risk\"Each treatment was enclosed in a sealed envelope, which was opened only after the physician in charge had decided to recruit the patient into the study\".Blinding (performance bias and detection bias) Objective outcome: DeathLow riskTrial authors provided no information on blinding.\
However, lack of blinding is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskTrial authors provided no information on blinding, however it may not be feasible due to different routes of administration for both interventions.Incomplete outcome data (attrition bias) All outcomesLow riskLoss to follow‐up about 5%.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0007]MethodsTrial design: Open RCT\
Trial dates: June 1993 to February 1994 and June 1994 to December 1994ParticipantsNumber of participants: 67 children aged three months to 15 years enrolled\
Inclusion criteria: Fever (core temperature ≥ 38 °C), positive blood smear for *P. falciparum* with ≥ 0.1% of parasitized erythrocytes, one major criterion or two minor criteria for severe malaria cases (WHO criteria) and parental consent\
Exclusion criteria: Patients with infection who had been treated within 24 hours with quinine or intramuscular injection was not eligible.Interventions1. Intramuscular artemether (Paluther)\
Loading dose of 3.2 mg/kg on admission (two times)Followed by 1.6 mg/kg once daily for four days\
2. Intravenous quinine\
Loading dose of 20 mg/kg on admissionFollowed by 10 mg/kg every eight hours until oral drug administration was possible (10 mg/kg every eight hours)OutcomesOutcomes included in the review:\
DeathComa resolution timeFever clearanceParasite clearanceAdverse events\
Outcomes not included in the review:\
RecrudescenceNotesLocation: Gabriel Touré\'s Hospital, Mali\
Transmission: Unknown\
Funding: Rhône‐Poulenc Rorer Doma (France)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskCentral randomization by clinical monitor.Allocation concealment (selection bias)Low riskOpaque envelopes used to conceal allocation.Blinding (performance bias and detection bias) Objective outcome: DeathLow riskAn open‐label trial is unlikely to bias an objective outcome like death.\
No blinding is described, and blinding would not be feasible.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskAn open‐label trial.Incomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐up reported.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0008]MethodsTrial design: Open RCT\
Trial dates: Not statedParticipantsNumber: 160 children aged five months to 12 years enrolled\
Inclusion criteria: Children were admitted to the trial if they had *P. falciparum* asexual parasitaemia, were comatose and parental consent was obtained.\
Exclusion criteria: Children were excluded if there was evidence of a pre‐existing neurological deficit, head injury, or history of recent treatment with antimalarial drugs other than chloroquine.Interventions1. Intramuscular artemether (Paluther, Rhône‐Poulenc)\
Loading dose of 3.2 mg/kgFollowed by 1.6 mg/kg once daily. At least three doses of artemether were givenFollowed by sulphadoxine‐pyrimethamine if parasitaemia had cleared and the child could drink. Otherwise artemether was continued for a total of five days (four maintenance doses)\
2. Intravenous quinine (Laboratoires Renaudin, Paris)\
Loading dose of 20 mg/kg infused over four hoursFolowed by 10 mg/kg every eight hours with dose given over two hours. At least three doses of parenteral quinine were given, and continued until the child was able to drink and parasitaemia had clearedThen a single dose of sulphadoxine‐pyrimethamine (sulphadoxine 25 mg/kg, pyrimethamine 1.25 mg/kg) given orally or intramuscularlyOutcomesOutcomes included in the review:\
Time to deathComa resolutionNeurological sequelaeFever clearanceParasite clearanceAdverse effects\
Outcomes not included in the review:\
Mortality with respiratory distressNotesLocation: Kenya Medical Research Institute (KEMRI) Coastal Research Unit, Kilifi district hospital, Kenya.\
Transmission: Unknown\
Funding:\
KEMRIUNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)The Wellcome Trust***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskCentrally‐coded unique trial numbers.Allocation concealment (selection bias)Low riskSealed envelopes prepared by the clinical monitor.Blinding (performance bias and detection bias) Objective outcome: DeathLow riskAn open‐label trial is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskAn open‐label trial.\
Blinding unlikely as artemether and quinine were given by 2 different routes.Incomplete outcome data (attrition bias) All outcomesLow risk40 patients (14 from artemether arm and 26 from quinine arm) excluded. Mostly for not meeting inclusion criteria.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0009]MethodsTrial design: RCT\
Trial dates: Not statedParticipantsNumber of participants: 37 children enrolled (age range not stated)\
Inclusion criteria: Children with unrousable coma, asexual forms of *P. falciparum* parasitaemia and no other identifiable cause of coma.\
Exclusion criteria: None statedInterventions1. Intramuscular artemether\
Loading dose of 3.2 mg/kg on admissionFollowed by 1.6 mg/kg 12 hours laterThen 1.6 mg/kg once daily for two days\
2. Intravenous quinine\
Loading dose of 10 mg/kg infused over two hoursFollowed by 10 mg/kg every eight hours until patient regained consciousness then switched to oral dose for a total of seven daysOutcomesOutcomes included in the review:\
DeathComa resolution timeNeurologic sequelaeFever clearance timePercentage of children with parasites clearance at days 3 and 7\
Outcomes not included in the review: NoneNotesLocation: University of Ilorin Teaching Hospital, Nigeria\
Transmission: Unknown\
Funding: None stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Patients were randomly assigned to either of the two treatment modalities\".Allocation concealment (selection bias)Unclear riskInsufficient information about the sequence generation process to permit judgement.Blinding (performance bias and detection bias) Objective outcome: DeathLow riskUnlikely to be biased whether blinding was done or not.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskNo information about blinding provided by trial authors.\
Blinding unlikely as artemether and quinine were given by 2 different routes.Incomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐up recorded.Selective reporting (reporting bias)Low riskMost relevant outcomes reported.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0010]MethodsTrial design: Open label RCT\
Trial dates: Not statedParticipantsNumber of participants: 103 children aged 11 months to five years enrolled\
Inclusion criteria: Children aged six months to 5 years satisfying the WHO criteria for cerebral malaria, viz. unrousable coma lasting more than 30 minutes (with or without convulsions) with the presence of peripheral *P. falciparum* parasitaemia were included in the trial.\
Exclusion criteria: None statedInterventions1. Intramuscular artemether\
Loading dose of 3.2 mg/kg on admissionFollowed by 1.6 mg/kg once daily for four days\
2. Intravenous quinine (Lemquine®)\
Loading dose of 20 mg/kg infused over four hoursFollowed by 10 mg/kg infused over two hours given every eight hours until the patient is conscious and oral quinine continued at 10 mg/kg orally every eight hours to complete a total of 21 doses or seven days\
Loading dose quinine was omitted in patients with a positive history of quinine or mefloquine ingestion in the preceding 24 hours before hospital presentation.OutcomesOutcomes included in the review:\
DeathParasite clearance timeFever clearance timeSurvival and neurological symptomsComa recovery timeNeurological deficitsBlood transfusions\
Outcomes not included in the review:\
Time to full ambulationNotesLocation: Emergency Paediatric ward, University College Hospital, Ibadan, Nigeria\
Transmission: Unknown\
Funding: World Bank/UNDP/WHO special fund for Research and Training in Tropical Diseases (TDR)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated allocation.Allocation concealment (selection bias)Unclear riskMethods not described by trial authors.Blinding (performance bias and detection bias) Objective outcome: DeathLow riskUnlikely to be biased whether blinding was done or not.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskNo information of blinding reported by authors.\
Blinding unlikely as artemether and quinine were given by 2 different routes.Incomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐up recorded.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0011]MethodsTrial design: RCT\
Trial dates: Not statedParticipantsNumber: 32 children aged one to 12 years enrolled\
Inclusion criteria: Children aged one to 12 years, with fever (temperature \> 37.5°C), presence of convulsion, vomiting, hypoglycaemia, anaemia and headache. Informed consent obtained from the parents and guardians. Assurance that patients will be resident within catchments of trial for follow‐up. Absence of concomitant illness such as bronchopneumonia, typhoid, meningitis, urinary tract infection.\
Exclusion criteria: History of blood transfusion in the last two months, presence of concomitant illness, history of previous allergy to quinine and artemether.Interventions1. Intramuscular artemether (Rhône‐Poulence, Rorer France)\
Loading dose of 1.6 mg/kg twice on day 0Followed by 1.6 mg/kg once daily for the next four days\
2. Intravenous quinine (Evans)\
Loading dose of 10 mg/kg infused over four hoursFollowed by 10 mg/kg given at eight hour intervals and oral quinine (10 mg/kg body weight, eight hour intervals) as soon as the patient\'s condition allowed.\
Treatment with quinine was for a total of seven days.OutcomesOutcomes included in the review:\
Coma resolution timeFever clearance timeParasite clearance time\
Outcomes not included in the review: NoneNotesLocation: Overcomers Specialist Clinic Ileshan and General Hospital Ikenne, Nigeria\
Transmission: Unknown\
Funding: None stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"The children were randomly allocated into 2 treatment groups; treatment Q and A for quinine and artemether respectively\".Allocation concealment (selection bias)Unclear riskNo information on allocation concealment provided by trial authors.Blinding (performance bias and detection bias) Objective outcome: DeathLow riskUnlikely to be biased whether blinding was done or not.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskNo information of blinding reported by authors.\
Blinding unlikely as artemether and quinine were given by two different routes.Incomplete outcome data (attrition bias) All outcomesLow riskAttrition about 6% and not likely to affect outcomes.Selective reporting (reporting bias)Low riskNo evidence of selective reporting. Authors have published three outcomes in three different publications from the same trial.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0012]MethodsTrial design: Double blind RCT\
Trial dates: May 1996 to June 2003ParticipantsNumber of participants: 370 adults aged between 15 and 77 years enrolled\
Inclusion criteria: Peripheral blood smears had asexual forms of *P. falciparum* and had at least one of the following severe complications: cerebral malaria (Glasgow Coma Score was less than 11), renal acute failure (oliguria and serum creatinine \> 250 μmol/L), jaundice (total serum bilirubin \> 50 μmol/L) with a parasite count of more than 100,000/μL or with serum creatinine \> 250 μmol/L, hypoglycaemia (blood glucose \< 2.2 mmol/L), anaemia (haematocrit \< 20%) with a parasite count of more than 100,000/μL, hyperparasitaemia (parasite count \> 500,000/μL), hyperlactataemia (plasma lactate \> 4 mmol/L), metabolic acidosis (standard base excess \> ‐ 5 mmol/L, base deficit \< 10 mmol/L) and shock (systolic blood pressure \< 80 mmHg with cool extremities).\
Exclusion criteria: Patients were not included if they were \< 14 years, were pregnant in the first trimester, were known intravenous drug abusers, had received more than 3 g of quinine or two doses of any artemisinin derivatives in the previous 48 hours before admission, had a past history of allergy to any artemisinin derivatives, or if known to be HIV positive.Interventions1.Intramuscular artemether (Kunming Pharmaceutical Company, Kunming, China)\
Loading dose of 3.2 mg/kgFollowed by 1.6 mg/kg daily for at least two days\
2.Intramuscular artesunate (Guilin No 2 Pharmaceutical Factory, Guangxi,China)\
Loading dose of 2.4 mg/kg on admissionFollowed by 1.2 mg/kg once daily for at least two daysFollowed by 2 mg/kg of oral artesunate to complete a total of seven daysOutcomesOutcomes included in the review:\
DeathComa resolution timeTime to dischargeFever clearance timeParasite clearance timeEpisodes of hypoglycaemiaAdverse effects\
Outcomes not included in the review:\
Time to drinkingTime to eatingTime to sittingTime to standingTime to walkingNotesLocation: Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam\
Transmission: Not stated\
Funding: Wellcome Trust, UK***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"The randomization was generated from random number tables\".Allocation concealment (selection bias)Low risk\"Labels with the name of drug for each patient were put in coded sealed opaque envelopes, and the envelopes were randomized in blocks of 20. Once a patient was enrolled in the study the envelope was opened\".Blinding (performance bias and detection bias) Objective outcome: DeathLow risk\"An independent team of nurses, not otherwise involved in the study or responsible for the care of these patients, open the envelope, randomized the patient and prepared the injection. Neither the treating physicians, study doctors and nurses, or patients knew which anti‐malarial drugs was administered\".Blinding (performance bias and detection bias) Subjective outcomes: OthersLow risk\"An independent team of nurses, not otherwise involved in the study or responsible for the care of these patients, open the envelope, randomized the patient and prepared the injection. Neither the treating physicians, study doctors and nurses, or patients knew which anti‐malarial drugs was administered\".Incomplete outcome data (attrition bias) All outcomesLow riskNo loss to follow‐up recorded.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0013]MethodsTrial design: RCT\
Trial dates: May 1995 to June 1996ParticipantsNumber: 77 children enrolled aged three months to 15 years\
Inclusion criteria: Children who satisfied the WHO criteria for diagnosis of cerebral malaria (such as unrousable coma for at least half an hour following convulsions, positive blood film for malaria, exclusion of other causes of encephalopathy and informed consent by parent or guardian).\
Exclusion criteria: Concomitant acute illness such as pneumonia, meningitis or acute renal failure and any contraindication to IM injection.Interventions1.Intramuscular artemether\
Loading dose of 1.6 mg/kg, repeated after 12 hoursFollowed by 1.6 mg/kg once daily for four days\
2. Intravenous quinine\
Loading dose of 10 mg/kgFollowed by 10 mg/kg repeated every eight hours and changed to oral dose when patient was able to drink.\
Treatment with quinine was for a total of seven daysOutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelaeFever clearance timeParasite clearance time\
Outcomes not included in the review:\
28^th^ day cure rateNotesLocation: Khartoum Children\'s Emergency Hospital and Ahmed Gasim Specialist Hospital for Children, Sudan\
Transmission: Unknown\
Funding:\
Danish Development Agency (DANIDA)German Academic Exchange Service (DAAD)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"The cases were randomly allocated into two groups\".Allocation concealment (selection bias)Unclear riskNo information provided by trial authors about allocation concealment.Blinding (performance bias and detection bias) Objective outcome: DeathLow riskUnlikely to be biased whether blinding was done or not.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskNo information of blinding reported by authors.\
Blinding unlikely as artemether and quinine were given by 2 different routes.Incomplete outcome data (attrition bias) All outcomesHigh risk\> 10% of participants in each arm dropped out before Day 28.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0014]MethodsTrial design: Open‐label, RCT\
Trial dates: June 1992 to May 1995ParticipantsNumber: 33 adults aged above 12 years\
Inclusion criteria: Blood smear showed asexual forms of *P. falciparum*; in addition to fulfilling one or more of the WHO criteria for severe or complicated malaria\
Exclusion criteria: Patients under the age of 12 years, pregnant women, those who had received parenteral antimalarial treatment prior to admission and those with a co‐existent bacterial, viral, fungal or mixed malarial infection were excluded.Interventions1. Intramuscular artemether (Rhone‐Poulenc Rorer)\
Loading dose of 3.2 mg/kgFollowed by 1.6 mg/kg once daily for 4 days\
2. Intravenous Quinine (Medipharma)\
Loading dose of 20 mg/kgFollowed by 10 mg/kg eight hourly and patients able to tolerate oral medication were switched to oral quinine after 48hours to complete a total of seven days.OutcomesOutcomes included in the review:\
DeathComa resolution timeFever clearance timeParasite clearance timeEpisodes of hypoglycaemiaAdverse effects\
Outcomes not included in the review:NoneNotesLocation:Port Moresby General Hospital, Papua New Guinea\
Transmission: Seasonal/Sporadic\
Funding:\
UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)Colt FoundationWellcome Trust***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskPatients were randomly assigned to treatment with quinine or artemether.Allocation concealment (selection bias)Low riskEnvelopes containing the assigned treatment were opened sequentially when a patient was recruited.Blinding (performance bias and detection bias) Objective outcome: DeathLow riskUnlikely to be biased whether blinding was done or not.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskNo information of blinding reported by authors.\
Blinding unlikely as artemether and quinine were given by two different routes.Incomplete outcome data (attrition bias) All outcomesHigh riskDifferential proportion of withdrawals from both arms (25% versus 10%).Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0015]MethodsTrial design: Open label RCT\
Trial dates: January 1992 to June 1994ParticipantsNumber: 183 children enrolled (age range not stated)\
Inclusion criteria: Children with asexual forms of *P. falciparum* detected in a peripheral blood smear, and a Blantyre Coma Score ≤ 2, and if no other cause of fever or altered consciousness could be discovered.\
Exclusion criteria: None statedInterventions1. Intramuscular artemether\
Loading dose of 3.2 mg/kg on admissionFollowed by 1.6 mg/kg once daily. A minimum of three doses were given.Then oral sulphadoxine‐pyrimethamine (approximately 25 mg/kg sulphadoxine and 1.25 mg/kg pyrimethamine) if parasitaemia had cleared and the patient was fully conscious.\
2. Intravenous quinine\
Loading dose of 20 mg/kg infused over four hours.Followed by 10 mg/kg infused over two hours at eight hour intervals. After a minimum of three intravenous quinine doses oral quinine given in 10 mg/kg doses at eight hour intervals if the patient was able to drinkThen oral sulphadoxine‐pyrimethamine (same as above).OutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelaeFever clearance timeParasite clearance time\
Outcomes not included in the review:\
Recurrent parasitaemiaReticulocyte responseNotesLocation: Paediatric ward at the Queen Elizabeth Central Hospital, Malawi\
Transmission: Unknown\
Funding: UNDP/World Bank/WHO special programme for research and training in tropical diseases (TDR)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlock randomization.Allocation concealment (selection bias)Low risk\"Randomized treatment assignments were prepared in blocks of ten by the sponsoring agency.Following initial stabilization, diagnosis and examination, a sealed envelope containing the treatment group was opened, and the patient was allocated to treatment\".Blinding (performance bias and detection bias) Objective outcome: DeathLow riskAn open‐label trial is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskAn open‐label trial.Incomplete outcome data (attrition bias) All outcomesHigh riskDifferential proportion of withdrawals from both arms (13% versus 8%).Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0016]MethodsTrial design: Open label trial\
Trial dates: 1992 to 1994ParticipantsNumber: 576 children aged one to nine years enrolled\
Inclusion criteria: Unconscious children one to nine years of age with a Blantyre coma score of 2 or less, asexual forms of *P. falciparum* were identified on a thick blood film, and a parent or guardian gave informed consent.\
Exclusion criteria: Patients with diseases other than malaria at the time of admission and those who recovered consciousness immediately after correction of hypoglycaemia or within one hour if they were convulsing on admission. Patients treated with quinine before admission.Interventions1. Intramuscular artemether (Paluther, Rhone‐Poulenc)\
Loading dose of 3.2 mg/kg on admissionFollowed by daily doses of 1.6 mg/kg for three days\
2. Intravenous quinine (Rotexmedica, Germany)\
Loading dose of 20 mg/kgFollowed by 10 mg/kg every 12 hoursThen oral quinine once patient was able to swallow for a total of five days\
An oral dose of approximately 1.25 mg/kg pyrimethamine and 25 mg/kg sulfadoxine was given to both arms to reduce recrudescence (in the 2nd and 3rd years of the trial).OutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelae at dischargeNeurological sequelae at 28 daysFever clearance timeParasite clearance timeAdverse effects\
Outcomes not included in the review:\
Residal neurological sequelae (five months follow‐up)28th day cure rateNotesLocation: Royal Victoria Hospital and Sibanor Health Centre,Banjul Gambia\
Transmission:Unknown\
Funding:\
UNDP/World Bank/WHO special programme for research and training in tropical diseases (TDR)The Netherlands Foundation for the Advancement of Tropical ResearchThe Ter Meulen FoundationThe Medical Research Council***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskTrial authors do not provide details of sequence generationAllocation concealment (selection bias)Low risk\"The treatment code for each child was stored in a sealed envelope that was opened after the admission procedure was completed and parental consent had been obtained\".Blinding (performance bias and detection bias) Objective outcome: DeathLow riskAn open‐label trial is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias) Subjective outcomes: OthersLow risk\"Each blood film was examined by two independent observers who were unaware of the treatment code\".Incomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐up were recorded.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0017]MethodsTrial design: Open RCT\
Trial dates: March 1992 to September 1994ParticipantsNumber: 124 adults aged between 16 and 66 years\
Inclusion criteria: 15 years of age or older, with clinical symptoms and signs of malaria and the presence of asexual forms of *P. falciparum* in their peripheral blood. In addition to having at least one of the following signs: (i) unrousable coma (Glasgow coma score \< ll); (ii) hypoglycaemia (blood glucose \< 2.2 mmol/L (40 mg %); (iii) acute renal failure (plasma creatinine \> 265.2 µmol/L (3 mg %) with or without oliguria); (iv) jaundice (total bilirubin \> 51.3 mol/L (3 mg %)) with parasitaemia \> 100,000/µL or with plasma creatinine \>1.5 mg %; (v) anaemia (haematocrit \< 20%) with parasitaemia \> 100000/µL; (vi) shock (systolic arterial pressure \< 80 mmHg with a thready pulse and cold clammy extremities); and (vii) hyper parasitaemia \>500000/µL.\
Exclusion criteria: Patients were excluded from the trial if prior treatment with more than 3 g of quinine or two doses of artemisinin or a derivative had been recorded by the peripheral health care worker. Pregnant patients in the first trimester, and patients with concomitant diseases (such as active tuberculosis, bacterial meningitis), or mixed infections with *P. vivax* were also excluded from the trial.Interventions1.Intramuscular artemether (Kunming Pharmaceutical, Yunnan, China)\
Loading dose of 200 mgFollowed by 100 mg once daily for three days\
2.Intramuscular artesunate (Guilin No. 2 Pharmaceutical Factory, Guangxi, China)\
Loading dose of 120 mgFollowed by 60 mg once daily for three days\
3. Intravenous artesunate (Guilin No. 2 Pharmaceutical Factory, Guangxi, China)\
Loading dose of 120 mgFollowed by 60 mg once daily for three days\
All patients received 750 mg mefloquine (Lariam®, Roche) as a single dose after regaining consciousness or at day 4.OutcomesOutcomes included in the review:\
DeathComa resolution timeFever clearance timeParasite clearance time\
Outcomes not included in the review:\
Fatality rateNotesLocation: Tan Phu regional Hospital, Vietnam\
Transmission: Endemic\
Funding: Roche Asian Research Foundation, Hong Kong***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskTrial authors do not provide details about random sequence generation.Allocation concealment (selection bias)Low risk\"When a patient fulfilled the enrolment criteria, a sealed envelope containing the code for the treatment regimen was opened to allocate him/her to one of the following 4 treatment groups\".Blinding (performance bias and detection bias) Objective outcome: DeathLow riskDescribed as open‐label. However, lack of blinding is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh riskAn open‐label trial.Incomplete outcome data (attrition bias) All outcomesLow riskNo losses to follow‐up were reported.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.[@CD010678-bbs2-0018]MethodsTrial design: Open RCT\
Trial dates: Not statedParticipantsNumber: 54 children aged one to five years enrolled\
Inclusion criteria: Patients were admitted if they satisfied the strict WHO definition of cerebral malaria.\
Exclusion criteria: None statedInterventions1. Intramuscular artemether\
Loading dose of 3.2 mg/kg on admissionFollowed by 1.6 mg/kg for four days\
2. Intravenous quinine\
Loading dose of 20 mg/kg infused over four hours on admissionFollowed by 10 mg/kg every eight hours until patient regained consciousness and oral medication was continued at 10 mg/kg, every eight hours for a total of seven daysOutcomesOutcomes included in the review:\
DeathComa resolution timeNeurological sequelaeFever clearance timeParasite clearance timeAdverse effects\
Outcomes not included in the review:\
Time to sit unaidedTime to drinkDischarge packed cell volumeMortality rate28th day cure rateParasite recrudescenceNotesLocation: University College Hospital, Ibadan, Nigeria\
Transmission:Unknown\
Funding: World Bank/UNDP/WHO special fund for Research and Training in Tropical Diseases (TDR)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom numbers used.Allocation concealment (selection bias)Low risk\"Each child was then assigned a random number from a list prepared by an independent collaborator and thus allocated at random to receive either intramuscular artemether or intravenous quinine\".Blinding (performance bias and detection bias) Objective outcome: DeathLow riskAn open‐label trial is unlikely to bias an objective outcome like death.Blinding (performance bias and detection bias) Subjective outcomes: OthersHigh risk\"This was a randomized, open, controlled study in which no attempt was made to 'blind' the investigators, as the test drug and the control drug were given by 2 different routes\".Incomplete outcome data (attrition bias) All outcomesLow riskOnly one patient excluded from fever clearance time outcome assessment because of urinary tract infection.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo other bias identified.

Characteristics of excluded studies \[ordered by study ID\] {#CD010678-sec2-0016}
===========================================================

StudyReason for exclusion[@CD010678-bbs2-0019]Intervention was rectal artemisinin.[@CD010678-bbs2-0020]Not a RCT.[@CD010678-bbs2-0021]Drug‐resistant malaria not severe malaria.[@CD010678-bbs2-0022]Uncomplicated malaria.[@CD010678-bbs2-0023]Comparison not parenteral treatment.[@CD010678-bbs2-0024]Not a RCT.[@CD010678-bbs2-0025]Comparison not parenteral treatment.[@CD010678-bbs2-0026]Not a RCT.[@CD010678-bbs2-0027]Not a RCT.[@CD010678-bbs2-0028]No desired review outcomes.[@CD010678-bbs2-0029]Patients not randomly selected (non‐probability consecutive sampling used).[@CD010678-bbs2-0030]Design is a case‐control prospective study.[@CD010678-bbs2-0031]Not a RCT.[@CD010678-bbs2-0032]Participants in the artemether arm also received single dose of mefloquine.[@CD010678-bbs2-0033]Participants not randomized.

Characteristics of studies awaiting assessment \[ordered by study ID\] {#CD010678-sec2-0017}
======================================================================

[@CD010678-bbs2-0034]MethodsMulticentre trialParticipantsInformation not availableInterventionsInformation not availableOutcomesInformation not availableNotesInformation not available[@CD010678-bbs2-0035]MethodsRCTParticipants105 adults enrolledInterventionsInformation not availableOutcomesInformation not availableNotesInformation not available

Ekpereonne Esu (EE) and Emmanuel E. Effa (EEE) identified and extracted data from eligible trials for this review. EE entered data into [@CD010678-bbs2-0052]. EEE and EE performed risk of bias assessment and analysed data. EE prepared the \'Summary of findings\' tables and the first draft of the review. All authors read, gave input to all sections and approved the final version.

Internal sources {#CD010678-sec2-0013}
================

University of Calabar, Nigeria.Liverpool School of Tropical Medicine, UK.

External sources {#CD010678-sec2-0014}
================

Department for International Development, UK.

None known.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^ No serious risk of bias: Trials were variable in their risk of bias, but exclusion of the trials at high or unclear risk of selection bias did not change this result. ^2^ No serious inconsistency: None of the individual trials found statistically significant effects, and there was no statistical heterogeneity between trials. ^3^ No serious indirectness: Trials were from West Africa, East Africa and one from India. All were in children with severe malaria (aged under 15 years), and most compared the standard dose of intramuscular artemether with the WHO recommended dose of intravenous quinine. ^4^ Downgraded by 1 for serious imprecision: These trials, and the overall meta‐analysis are underpowered to detect a difference or to prove equivalence. ^5^ Downgraded by 2 for serious risk of bias: Four of the six trials were at unclear risk of selection bias. When these four trials are excluded the result becomes non‐significant. ^6^ No serious inconsistency: Statistically significant differences were only seen in two of the six trials. However, statistical heterogeneity between trials was low and the overall meta‐analysis is statistically significant. ^7^ No serious imprecision: The result is statistically significant and the overall meta‐analysis is adequately powered to detect this effect. ^8^ Downgraded by 2 for very serious imprecision: These trials, and the overall meta‐analysis are underpowered to detect a difference or to prove equivalence. The 95% CI is very wide and includes clinically important differences and no effect. ^9^ Downgraded by 1 for serious inconsistency: The mean difference in parasite clearance time ranged from a two hour increase with artemether to a 15 hour decrease. ^10^ Downgraded by 1 for serious risk of bias: Four of the seven trials were at unclear risk of selection bias. When these four trials are excluded the result becomes non‐significant. ^11^ Downgraded by 1 for serious inconsistency: The mean difference in fever clearance time ranged from a 25 hour increase with artemether to an 18 hour decrease. ^12^ No serious imprecision: The overall meta‐analysis is powered to detect this effect. The result is statistically significant but may not be clinically important.

[^3]: ^1^ No serious risk of bias: Trials are generally well conducted and at low risk of bias. ^2^ No serious inconsistency: Statistically significant differences were only seen in one of the four trials. However, statistical heterogeneity between trials was low and the overall meta‐analysis is statistically significant. ^3^ No serious indirectness: All four trials compared intramuscular artemether with intravenous quinine in adults; two trials from Thailand, one each from Vietnam and Papua New Guinea ^4^ Downgraded by 1 for serious imprecision: These trials, and the overall meta‐analysis are very underpowered to detect a difference in mortality or to prove equivalence. ^5^[@CD010678-bbs2-0003] and [@CD010678-bbs2-0006] reported median coma time for artemether vs. quinine ([@CD010678-bbs2-0003]: 66 vs. 48, P = 0.003; [@CD010678-bbs2-0006]: 48 vs. 48). Downgraded by 1 for inconsistency: One trial found a shorter median coma resolution time with quinine, and one trial found no difference. ^6^ Downgraded by 1 for imprecision: The data could not be pooled.

    ^7^ No serious risk of bias: This single trial was at low risk of bias.

    ^8^ Downgraded by 1 for serious imprecision: Neurological sequelae in adults were uncommon. This trial is underpowered to detect or exclude clinically important differences. ^9^ Two trials found no significant difference between parasite clearance time for artemether vs. quinine ([@CD010678-bbs2-0005]: mean 63.6 vs. 61.6, P = 0.85 and [@CD010678-bbs2-0014]: median 48 vs. 52, P = 0.381). Two other trials reported significantly shorter median parasite clearance times for artemether vs. quinine ([@CD010678-bbs2-0003]: 72 vs. 90 P \< 0.001 and [@CD010678-bbs2-0006]: 54 vs.78, P = 0.007). No serious inconsistency: The two largest trials both found shorter median clearance times with artemether. ^10^ Three trials ([@CD010678-bbs2-0003], [@CD010678-bbs2-0014] and [@CD010678-bbs2-0006]) reported median fever clearance time for artemether vs. quinine (127 vs. 90, P \< 0.001; 32 vs. 48, P =  0.034 and 79 vs. 84, no significant difference). [@CD010678-bbs2-0005]reported mean fever clearance time and found a statistically significant reduction of about 30 hours with artemether. Downgraded by 1 for inconsistency: One trial found a shorter median fever clearance time with quinine, and two trials found a shorter time with artemether.

[^4]: ^1^ No serious risk of bias: Trials were generally well conducted and at low risk of bias. ^2^ No serious inconsistency: There is no statistical heterogeneity ^3^ No serious indirectness: The two trials were conducted in Vietnam and Thailand and both compared intramuscular artemether with intravenous artesunate in adults. ^4^ Downgraded by 1 for serious imprecision: These trials, and the overall meta‐analysis are very underpowered to detect a difference in mortality or to prove equivalence. ^5^[@CD010678-bbs2-0012] and [@CD010678-bbs2-0017] reported median coma resolution time for artemether vs. artesunate ([@CD010678-bbs2-0012]: 72 vs. 60, P = 0.11; [@CD010678-bbs2-0017]: 47 (artemether) vs. 30 (artesunate IM) vs. 24 (artesunate IV). No serious inconsistency: Both trials suggest an advantage with artesunate although not statistically significant. ^6^ Downgraded by 1 for serious imprecision: We could not pool these data as median data were presented for both trials. ^7^[@CD010678-bbs2-0012] and [@CD010678-bbs2-0017] reported median parasite clearance time ([@CD010678-bbs2-0012]: 72 vs. 72, P = 0.97; [@CD010678-bbs2-0017]: 30 (artemether) vs. 24 (artesunate IM) vs. 24 (artesunate IV). No serious inconsistency: Both trials found no difference between treatments. ^8^[@CD010678-bbs2-0012] and [@CD010678-bbs2-0017] reported median fever clearance time ([@CD010678-bbs2-0012]: 108 vs. 108, P = 0.27; [@CD010678-bbs2-0017]: 48 (artemether) vs. 36 (artesunate IM) vs. 30 (artesunate IV). No serious inconsistency: Both trials found no statistically significant difference between artemether and artesunate.

[^5]: ^1^Cochrane Infectious Diseases Group Specialized Register. ^2^Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration ([@CD010678-bbs2-0046]).

[^6]: IM = intramuscular; IV = intravenous; SP = sulphadoxine‐pyrimethamine.

    ^1^Only in the second and third years of the study.

[^7]: IM = intramuscular; IV = intravenous.

[^8]: IM = intramuscular; IV = intravenous.

[^9]: WBC = white blood cell.

[^10]: ^1^ These calculation were performed using a power calculator available at: http://www.sealedenvelope.com/power/ ^2^ All calculation were performed for a power of 80% and an α error of 0.05. ^3^ The proportion in the control group is taken from the median control group risk across trials. ^4^ A maximum 3% risk difference was chosen to represent equivalence.

[^11]: ^1^ These calculations were performed using a power calculator available at: http://www.sealedenvelope.com/power/ ^2^ All calculation were performed for a power of 80% and an α error of 0.05. ^3^ The mean in the control group is taken from the median control group across studies. ^4^ A six‐hour time difference was chosen to represent a clinically important benefit.

[^12]: IQR = interquartile range.

[^13]: IQR = interquartile range.

[^14]: IM = intramuscular; IV = intravenous.
